{
  "questions": [
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/29610180",
        "http://www.ncbi.nlm.nih.gov/pubmed/1818237"
      ],
      "snippets": [
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Blue diaper syndrome (BDS) (Online Mendelian Inheritance in Man number 211000) is an extremely rare disorder that was first described in 1964. The characteristic finding is a bluish discoloration of urine spots in the diapers of affected infants. Additional clinical features of the first described patients included diarrhea, inadequate weight gain, hypercalcemia, and nephrocalcinosis. An intestinal defect of tryptophan absorption was postulated as the underlying pathology.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29610180",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 477
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "We describe the ocular abnormalities seen in a new metabolic disease which is deficient in the transport of tryptophan. ",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1818237",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 120
        }
      ],
      "id": "63f57d9b33942b094c000004",
      "type": "factoid",
      "body": "Which amino acid in implicated in the Blue diaper syndrome?"
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/35690812",
        "http://www.ncbi.nlm.nih.gov/pubmed/35562901",
        "http://www.ncbi.nlm.nih.gov/pubmed/36002248",
        "http://www.ncbi.nlm.nih.gov/pubmed/35856812",
        "http://www.ncbi.nlm.nih.gov/pubmed/35921234",
        "http://www.ncbi.nlm.nih.gov/pubmed/35140269"
      ],
      "snippets": [
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Targeted knockout of the SOX9 gene, which plays a role in the differentiation of mesenchymal progenitor cells into chondrocytes, ",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35690812",
          "offsetInBeginSection": 1369,
          "offsetInEndSection": 1498
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": ". SOX9 is a transcription factor with critical roles during neurodevelopment, particularly within neural stem cells.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35562901",
          "offsetInBeginSection": 64,
          "offsetInEndSection": 180
        },
        {
          "beginSection": "title",
          "endSection": "title",
          "text": "Epithelial SOX9 drives progression and metastases of gastric adenocarcinoma by promoting immunosuppressive tumour microenvironment.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36002248",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 131
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "any cancers engage embryonic genes for rapid growth and evading the immune system. SOX9 has been upregulated in many tumours, yet the role of SOX9 in mediating immunosuppressive tumour microenvironment is unclear. ",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36002248",
          "offsetInBeginSection": 12,
          "offsetInEndSection": 226
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Epithelial SOX9 is critical in suppressing CD8+ T cell responses and modified macrophage function in GAC through the paracrine LIF factor. Cotargeting LIF/LIFR and CSF1R has great potential in targeting SOX9-mediated cancer stemness,",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36002248",
          "offsetInBeginSection": 1454,
          "offsetInEndSection": 1687
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "S: In PCL of humans and mice, the expression of SP, SOX9, and MMP13 was upregulated as OA progressed, but their expression was downregulated in severe degeneration. SP and SOX9 were co-expressed in chondrocyte-like cells. In ligament cells, SP agonists downregulated SOX9, ",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35856812",
          "offsetInBeginSection": 898,
          "offsetInEndSection": 1171
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Sox9 plays an essential role in mammalian testis formation. It has been reported that gene expression in the testes is regulated by enhancers",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35921234",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 141
        },
        {
          "beginSection": "title",
          "endSection": "title",
          "text": "SOX9 and SRY binding sites on mouse mXYSRa/Enh13 enhancer redundantly regulate Sox9 expression to varying degrees.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35921234",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 114
        },
        {
          "beginSection": "title",
          "endSection": "title",
          "text": "Sox9 is involved in the thyroid differentiation program and is regulated by crosstalk between TSH, TGFβ and thyroid transcription factors",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35140269",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 137
        }
      ],
      "id": "642f4aac57b1c7a315000015",
      "type": "summary",
      "body": "Explain the function of SOX9"
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/21926471",
        "http://www.ncbi.nlm.nih.gov/pubmed/15196553",
        "http://www.ncbi.nlm.nih.gov/pubmed/20886764"
      ],
      "snippets": [
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Ubiquitination is a post-translational modification that generally directs proteins for degradation by the proteasome or by lysosomes. However, ubiquitination has been implicated in many other cellular processes, including transcriptional regulation, DNA repair, regulation of protein-protein interactions and association with ubiquitin-binding scaffolds.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21926471",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 355
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Ubiquitin is best known for its function in targeting proteins for degradation by the proteasome. Recent studies have revealed several new functions of ubiquitin that are independent of proteasomal degradation. These functions include the novel signaling roles of ubiquitin in DNA repair and the activation of protein kinases such as IkappaB kinase.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15196553",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 349
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Ubiquitination ofendogenous proteins is one of the key regulatory steps that guides protein degradation through regulation of proteasome activity.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20886764",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 146
        }
      ],
      "id": "644ea20157b1c7a31500007a",
      "type": "list",
      "body": "What are the outcomes of ubiquitination?"
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/29624723"
      ],
      "snippets": [
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "To evaluate the safety, pharmacokinetics, and preliminary efficacy of RT001 in Friedreich\u0027s ataxia patients",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29624723",
          "offsetInBeginSection": 228,
          "offsetInEndSection": 335
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "The primary endpoints were safety, tolerability, and pharmacokinetic analysis. ",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29624723",
          "offsetInBeginSection": 652,
          "offsetInEndSection": 731
        }
      ],
      "id": "6440306357b1c7a315000046",
      "type": "list",
      "body": "What were the primary endpoints of the phase I/II double-blind, comparator-controlled trial of RT001 in Friedreich\u0027s ataxia patients?"
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/35850241"
      ],
      "snippets": [
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Friedreich\u0027s ataxia (FRDA) is an autosomal recessive neurodegenerative disorder caused by a triplet guanine-adenine-adenine (GAA) repeat expansion in intron 1 of the FXN gene, which leads to decreased levels of the frataxin protein.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35850241",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 232
        }
      ],
      "id": "6450ec0c57b1c7a31500008f",
      "type": "factoid",
      "body": "What is the cause of Friedreich\u0027s Ataxia (FA)?"
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/36448076",
        "http://www.ncbi.nlm.nih.gov/pubmed/31168954",
        "http://www.ncbi.nlm.nih.gov/pubmed/29951170",
        "http://www.ncbi.nlm.nih.gov/pubmed/28878924",
        "http://www.ncbi.nlm.nih.gov/pubmed/22136872",
        "http://www.ncbi.nlm.nih.gov/pubmed/20134385",
        "http://www.ncbi.nlm.nih.gov/pubmed/1559000",
        "http://www.ncbi.nlm.nih.gov/pubmed/23745227"
      ],
      "snippets": [
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Serpentine supravenous hyperpigmentation (SSH) is a unique type of chemotherapy-associated drug eruption, characterized by hyperpigmentation along the superficial venous network.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31168954",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 178
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Serpentine supravenous hyperpigmentation (SSH) is a rare vasculo-cutaneous entity that has been associated with peripheral infusion of chemotherapy agents, in particular 5-FU1-3, but also seen with docetaxel4,5, fotemustine6, and vinorelbine7. ",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29951170",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 244
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Serpentine supravenous hyperpigmentation is a peculiar cutaneous eruption that follows the path of vein after intravenous injection of the chemotherapeutic agent. ",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28878924",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 163
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Serpentine erythematous or hyperpigmented streaks along the superficial venous network proximal to the site of injection may occur as a distinctive eruption after infusion of several chemotherapeutic agents. ",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22136872",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 208
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Serpentine supravenous hyperpigmentation was the term coined by Hrushesky to describe increased pigmentation of the skin immediately overlying the venous network used for intravenous infusion of 5-fluorouracil. ",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20134385",
          "offsetInBeginSection": 193,
          "offsetInEndSection": 404
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Two cases of serpentine supravenous hyperpigmentation developing in the area of fotemustine infusions are reported. ",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1559000",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 116
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "The serpentine supravenous hyperpigmentation on the lower extremities was uniform in width and color, which contrasts with the darker discoloration near the site of infusion seen with PSSH associated with chemotherapy.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23745227",
          "offsetInBeginSection": 695,
          "offsetInEndSection": 913
        }
      ],
      "id": "63eee73ef36125a426000003",
      "type": "list",
      "body": "What causes Serpentine Supravenous Hyperpigmentation?"
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/33352233",
        "http://www.ncbi.nlm.nih.gov/pubmed/17593875"
      ],
      "snippets": [
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Alpha-synuclein (a-syn) can aggregate and form toxic oligomers and insoluble fibrils which are the main component of Lewy bodies. Intra-neuronal Lewy bodies are a major pathological characteristic of Parkinson\u0027s disease (PD). These fibrillar structures can act as seeds and accelerate the aggregation of monomeric a-syn. Indeed, recent studies show that injection of preformed a-syn fibrils (PFF) into the rodent brain can induce aggregation of the endogenous monomeric a-syn resulting in neuronal dysfunction and eventual cell death. ",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33352233",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 535
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "A variety of gene mutations can cause familial forms of Parkinson\u0027s disease (PD) or amyotrophic lateral sclerosis (ALS). Mutations in the synaptic protein alpha-synuclein (alpha-Syn) cause PD.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17593875",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 192
        }
      ],
      "id": "644294b757b1c7a315000061",
      "type": "summary",
      "body": "Please summarize the relationship between a-syn and cell death."
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/10697588"
      ],
      "snippets": [
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Oncogenes are gain-of-function mutations of normal regulatory genes or proto-oncogenes. Originally discovered in retroviruses initiating a variety of animal and avian cancers, oncogenes are believed to be important contributors to human carcinogenesis. Proto-oncogenes are altered by point mutation, amplification or rearrangement.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10697588",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 331
        }
      ],
      "id": "644ef46557b1c7a315000083",
      "type": "factoid",
      "body": "What are positive cell-cycle regulators that can cause cancer when mutated called?"
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/27965672"
      ],
      "snippets": [
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Hereditary angioedema (HAE) is a rare autosomal dominant disorder caused by mutations of the SERPING1 or the Factor 12 genes.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27965672",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 125
        }
      ],
      "id": "6432fdd857b1c7a315000020",
      "type": "factoid",
      "body": "What is the inheritance pattern of hereditary angioedema?"
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/31467149"
      ],
      "snippets": [
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Friedreich\u0027s ataxia is classically considered a disease with onset in the first or second decade.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31467149",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 97
        }
      ],
      "id": "6450ede757b1c7a315000090",
      "type": "factoid",
      "body": "What is usually the onset age of Friedreich\u0027s Ataxia?"
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/35909375",
        "http://www.ncbi.nlm.nih.gov/pubmed/33630700",
        "http://www.ncbi.nlm.nih.gov/pubmed/26825319",
        "http://www.ncbi.nlm.nih.gov/pubmed/27797994"
      ],
      "snippets": [
        {
          "beginSection": "title",
          "endSection": "title",
          "text": "Cost-utility analysis of cemented hemiarthroplasty versus hydroxyapatite-coated uncemented hemiarthroplasty for the treatment of displaced intracapsular hip fractures : the World Hip Trauma Evaluation 5 (WHiTE 5) trial.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35909375",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 219
        },
        {
          "beginSection": "title",
          "endSection": "title",
          "text": "A randomized clinical trial of low dose single antibiotic-loaded cement versus high dose dual antibiotic-loaded cement in patients receiving a hip hemiarthroplasty after fracture: A protocol for the WHiTE 8 COPAL study.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33630700",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 219
        },
        {
          "beginSection": "title",
          "endSection": "title",
          "text": "The World Hip Trauma Evaluation Study 3: Hemiarthroplasty Evaluation by Multicentre Investigation - WHITE 3: HEMI - An Abridged Protocol.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26825319",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 137
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "METHODS AND ANALYSIS: The World Hip Trauma Evaluation (WHiTE) was set up to measure outcome in a comprehensive cohort of UK patients with hip fracture. ",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27797994",
          "offsetInBeginSection": 253,
          "offsetInEndSection": 405
        }
      ],
      "id": "63f03d58f36125a42600001f",
      "type": "factoid",
      "body": "What disease was the topic of the World Hip Trauma Evaluation (WHiTE) trial?"
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/36311548",
        "http://www.ncbi.nlm.nih.gov/pubmed/35653495",
        "http://www.ncbi.nlm.nih.gov/pubmed/34629180",
        "http://www.ncbi.nlm.nih.gov/pubmed/34585455",
        "http://www.ncbi.nlm.nih.gov/pubmed/35911352",
        "http://www.ncbi.nlm.nih.gov/pubmed/36002964"
      ],
      "snippets": [
        {
          "beginSection": "title",
          "endSection": "title",
          "text": "Challenges to the Diagnosis of Functional Neurological Disorder: Feigning, Intentionality, and Responsibility.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36311548",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 110
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "he diagnosis of Functional Neurological Disorder (FND) requires differentiation from other neurologic diseases/syndromes, and from the comparatively rare diagnosis of feigning (Malingering and Factitious Disorder)",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36311548",
          "offsetInBeginSection": 1,
          "offsetInEndSection": 214
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Functional neurological disorder reflects impairments in brain networks leading to distressing motor, sensory and/or cognitive symptoms that demonstrate positive clinical signs on examination incongruent with other conditions. ",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35653495",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 227
        },
        {
          "beginSection": "title",
          "endSection": "title",
          "text": "Functional neurological disorder and somatic symptom disorder in Parkinson\u0027s disease.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34629180",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 85
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "The occurrence of Functional Neurological Disorder (FND) and Somatic Symptom Disorder (SSD) in PD was not commonly accepted until recently, despite some evidence that emerged in the pre and early L-Dopa era. ",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34629180",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 208
        },
        {
          "beginSection": "title",
          "endSection": "title",
          "text": "Maladaptive schemas of patients with functional neurological symptom disorder.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34585455",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 78
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "he psychological underpinnings of functional neurological symptom disorders (FNSD) remain poorly understood. ",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34585455",
          "offsetInBeginSection": 13,
          "offsetInEndSection": 122
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "disintegration of explicit and implicit information processing in patients with FNSD has previously been suggested; however, this suggestion has so far received little empirical support. Trauma and maladaptive schemas probably reinforce disintegration in FNSD. The present study explored the occurrence of maladaptive schemas and investigated the impact of trauma-related maladaptive schemas in patients with FNSD.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34585455",
          "offsetInBeginSection": 124,
          "offsetInEndSection": 538
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Functional neurological symptom disorder (FND) remains a clinical challenge. It is one of the many mimics of cerebrovascular accidents, spinal cord disorders, and lower motor neuron disease. ",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35911352",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 191
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Previous studies with adults suggest that aberrant communication between neural networks underpins functional neurological disorder (FND). ",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36002964",
          "offsetInBeginSection": 12,
          "offsetInEndSection": 151
        }
      ],
      "id": "6436953757b1c7a315000028",
      "type": "yesno",
      "body": "Is Functional Neurological Disorder (FND) classified as a psychosomatic disorder?"
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/32142172",
        "http://www.ncbi.nlm.nih.gov/pubmed/31511305",
        "http://www.ncbi.nlm.nih.gov/pubmed/36069349"
      ],
      "snippets": [
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "In this review, it is argued that the relationship between the accessibility and activity of an enhancer is insufficiently described by simply considering open versus closed chromatin, or active versus inactive enhancers. Instead, recent studies focusing on the quantitative nature of accessibility signal reveal subtle differences between active enhancers and their different inactive counterparts: the closed silenced state and the accessible primed and repressed states. While the open structure as such is not a specific indicator of enhancer activity, active enhancers display a higher degree of accessibility than the primed and repressed states.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32142172",
          "offsetInBeginSection": 173,
          "offsetInEndSection": 825
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "DNA accessibility is thought to be of major importance in regulating gene expression.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31511305",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 85
        },
        {
          "beginSection": "title",
          "endSection": "title",
          "text": "Accessibility of promoter DNA is not the primary determinant of chromatin-mediated gene regulation.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31511305",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 99
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Euchromatin and heterochromatin have very similar accessibilities, suggesting that transcription factors can penetrate heterochromatin. Thus, DNA accessibility is not likely to be the primary determinant of gene regulation.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31511305",
          "offsetInBeginSection": 797,
          "offsetInEndSection": 1020
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "A major goal in the field of transcriptional regulation is the mapping of changes in the binding of transcription factors to the resultant changes in gene expression.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36069349",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 166
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Together, these results show many gene expression changes can happen independently of changes in the accessibility of local chromatin in the context of a single-factor perturbation.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36069349",
          "offsetInBeginSection": 1692,
          "offsetInEndSection": 1873
        }
      ],
      "id": "645004fa57b1c7a31500008b",
      "type": "yesno",
      "body": "Are accessible enhancers necessarily active?"
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/34573098"
      ],
      "snippets": [
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Omaveloxolone (RTA 408) is an activator of Nrf2 and an inhibitor of NFκB, possessing antioxidative and anti-inflammatory activities in mitochondrial bioenergetics. ",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34573098",
          "offsetInBeginSection": 690,
          "offsetInEndSection": 854
        }
      ],
      "id": "644008a657b1c7a31500003f",
      "type": "factoid",
      "body": "What is the alternative name of RTA 408?"
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/36375840",
        "http://www.ncbi.nlm.nih.gov/pubmed/35643151",
        "http://www.ncbi.nlm.nih.gov/pubmed/35614235",
        "http://www.ncbi.nlm.nih.gov/pubmed/35927425"
      ],
      "snippets": [
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "SMA is a monogenic pathology that originates from the loss of the SMN1 gene in most cases or mutations in rare cases. ",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36375840",
          "offsetInBeginSection": 167,
          "offsetInEndSection": 285
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Spinal muscular atrophy (SMA) is an autosomal recessive neurodegenerative disorder caused by defects in the survival motor neuron 1 (SMN1) gene.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35643151",
          "offsetInBeginSection": 12,
          "offsetInEndSection": 156
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Loss or deletion of survival motor neuron 1 gene (SMN1) is causative for a severe and devastating neuromuscular disease, Spinal Muscular Atrophy (SMA). ",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35614235",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 152
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Spinal muscular atrophy (SMA) is a neurodegenerative disorder caused by mutations in SMN1 (encoding survival motor neuron protein (SMN)). Reduced expression of SMN leads to loss of α-motor neurons, severe muscle weakness and often early death.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35927425",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 243
        }
      ],
      "id": "644640de57b1c7a31500006b",
      "type": "factoid",
      "body": "What is the cause of Spinal Muscular Atrophy (SMA)?"
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/35921451"
      ],
      "snippets": [
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "CONCLUSIONS: Prasinezumab therapy had no meaningful effect on global or imaging measures of Parkinson\u0027s disease progression as compared with placebo and was associated with infusion reactions. ",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35921451",
          "offsetInBeginSection": 2015,
          "offsetInEndSection": 2208
        }
      ],
      "id": "63eef9b6f36125a426000011",
      "type": "yesno",
      "body": "Is Prasinezumab effective for Parkinson’s Disease?"
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/35836081",
        "http://www.ncbi.nlm.nih.gov/pubmed/34281270",
        "http://www.ncbi.nlm.nih.gov/pubmed/28862809",
        "http://www.ncbi.nlm.nih.gov/pubmed/31670406"
      ],
      "snippets": [
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Luminopsins (LMOs) are chimeric proteins consisting of a luciferase fused to an opsin that provide control of neuronal activity",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31670406",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 127
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Previous work has demonstrated that fusion of a luciferase to an opsin, to create a luminescent opsin or luminopsin",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28862809",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 115
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "luminopsins, fusion proteins of light-generating luciferase and light-sensing ion channels that could be used to increase neuronal excitability if exposed to a suitable substrate",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34281270",
          "offsetInBeginSection": 362,
          "offsetInEndSection": 540
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "BL-OG is realized through opsin-luciferase fusion proteins called luminopsins (LMOs)",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35836081",
          "offsetInBeginSection": 499,
          "offsetInEndSection": 583
        }
      ],
      "id": "6419cd02690f196b5100003a",
      "type": "summary",
      "body": "What are Luminopsins?"
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/21376230"
      ],
      "snippets": [
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "The hallmarks of cancer comprise six biological capabilities acquired during the multistep development of human tumors. The hallmarks constitute an organizing principle for rationalizing the complexities of neoplastic disease. They include sustaining proliferative signaling, evading growth suppressors, resisting cell death, enabling replicative immortality, inducing angiogenesis, and activating invasion and metastasis. Underlying these hallmarks are genome instability, which generates the genetic diversity that expedites their acquisition, and inflammation, which fosters multiple hallmark functions. Conceptual progress in the last decade has added two emerging hallmarks of potential generality to this list-reprogramming of energy metabolism and evading immune destruction.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21376230",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 782
        }
      ],
      "id": "644f0ca257b1c7a315000089",
      "type": "list",
      "body": "What are the hallmarks of cancer?"
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/34322164"
      ],
      "snippets": [
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Recent results from the PEACHTREE trial (ClinicalTrials.gov Identifier: NCT02595398), a phase III trial with two suprachoroidal injections of CLS-TA at 0 and 12 weeks with follow up lasting 24 weeks, showed the significant improvement in visual acuity and reduction in central subfield thickness, all without increasing the risk of elevated intraocular pressure or accelerated cataract progression.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34322164",
          "offsetInBeginSection": 711,
          "offsetInEndSection": 1109
        }
      ],
      "id": "64403a5857b1c7a31500004c",
      "type": "factoid",
      "body": "What was the phase of the clinical trial PEACHTREE?"
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/16550925",
        "http://www.ncbi.nlm.nih.gov/pubmed/22103509",
        "http://www.ncbi.nlm.nih.gov/pubmed/31840275"
      ],
      "snippets": [
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Emery-Dreifuss muscular dystrophy (EDMD) is an inherited muscular disorder clinically characterized by slowly progressive weakness affecting humero-peroneal muscles, early joint contractures and cardiomyopathy with conduction defects. Autosomal dominant and recessive forms are caused by mutations in lamin A/C gene.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16550925",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 316
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "X-linked recessive form of EDMD is caused by mutation in EMD (or STA) gene ",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16550925",
          "offsetInBeginSection": 516,
          "offsetInEndSection": 591
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "The LINC components emerin, lamin A/C, SUN1, SUN2, nesprin-1 and nesprin-2 interact with each other at the NE and also with other binding partners including actin filaments and B-type lamins.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22103509",
          "offsetInBeginSection": 162,
          "offsetInEndSection": 353
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Emerin was the first LINC component associated with a human disease, namely EDMD (Emery-Dreifuss muscular dystrophy).",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22103509",
          "offsetInBeginSection": 473,
          "offsetInEndSection": 590
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Later on, other components of the LINC complex, such as lamins A/C and small isoforms of nesprin-1 and nesprin-2, were found to be associated with EDMD",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22103509",
          "offsetInBeginSection": 591,
          "offsetInEndSection": 742
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Only approximately 46% of the EDMD patients can be linked to genes of LINC and non-LINC components, pointing to further genes involved in the pathology of EDMD",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22103509",
          "offsetInBeginSection": 814,
          "offsetInEndSection": 973
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": " Recently, screening of binding partners of LINC components as candidates identified LUMA (TMEM43), encoding a binding partner of emerin and lamins, as a gene involved in atypical EDMD.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22103509",
          "offsetInBeginSection": 1030,
          "offsetInEndSection": 1215
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": " EDMD-causing mutations in STA/EMD (encoding emerin",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22103509",
          "offsetInBeginSection": 1303,
          "offsetInEndSection": 1354
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Emery-Dreifuss muscular dystrophy (EDMD) is a rare muscular dystrophy, but is particularly important to diagnose due to frequent life-threatening cardiac complications. EDMD classically presents with muscle weakness, early contractures, cardiac conduction abnormalities and cardiomyopathy, although the presence and severity of these manifestations vary by subtype and individual. Associated genes include EMD, LMNA, SYNE1, SYNE2, FHL1, TMEM43, SUN1, SUN2, and TTN, encoding emerin, lamin A/C, nesprin-1, nesprin-2, FHL1, LUMA, SUN1, SUN2, and titin, respectively.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31840275",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 564
        }
      ],
      "id": "6446838957b1c7a31500006e",
      "type": "list",
      "body": "Which genes are related to Emery-Dreifuss Muscular Dystrophy (EDMD)?"
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/35857660"
      ],
      "snippets": [
        {
          "beginSection": "title",
          "endSection": "title",
          "text": "Phase 1-2 Trial of AAVS3 Gene Therapy in Patients with Hemophilia B.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35857660",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 68
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "BACKGROUND: FLT180a (verbrinacogene setparvovec) is a liver-directed adeno-associated virus (AAV) gene therapy that uses a synthetic capsid and a gain-of-function protein to normalize factor IX levels in patients with hemophilia B",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35857660",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 230
        }
      ],
      "id": "63f02e1bf36125a426000016",
      "type": "yesno",
      "body": "Was AAVS3 developed for hemophilia A?"
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/35551298",
        "http://www.ncbi.nlm.nih.gov/pubmed/11512142",
        "http://www.ncbi.nlm.nih.gov/pubmed/17994900",
        "http://www.ncbi.nlm.nih.gov/pubmed/836795"
      ],
      "snippets": [
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "new firefly bioluminescence substrates, and further evaluated their activities in vitro and in vivo. It is worth noting that the maximum biological emission wavelength of novel luciferin analogue AL3 ((S,E)-2-(6-hydroxy-5-(3-methoxy-3-oxoprop-1-en-1-yl)benzo[d]thiazol-2-yl)-4,5-dihydrothiazole-4-carboxylic acid) is 100 nm red-shifted compared with D-luciferin, ",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35551298",
          "offsetInBeginSection": 224,
          "offsetInEndSection": 587
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "AL4 ((S,E)-2-(5-(2-cyanovinyl)-6-hydroxybenzo[d]thiazol-2-yl)-4,5-dihydrothiazole-4-carboxylic acid) ",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35551298",
          "offsetInBeginSection": 610,
          "offsetInEndSection": 711
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "The new substrate AL2 ((S,E)-2-(6-hydroxy-7-(3-methoxy-3-oxoprop-1-en-1-yl)benzo[d]thiazol-2-yl)-4,5-dihydrothiazole-4-carboxylic acid) showed better bioluminescence performance in vivo.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35551298",
          "offsetInBeginSection": 733,
          "offsetInEndSection": 919
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "The interaction of luciferases from two types of luminous bacteria, Photobacterium leiognathi and Vibrio harveyi, with their substrates [the photorecovered FMNH2 and long-chain aldehydes--decanal (C10), dodecanal (C12) and tetradecanal (C14)] ",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11512142",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 243
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Following coadministration of two luciferase substrates, native coelenterazine and luciferin,",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17994900",
          "offsetInBeginSection": 593,
          "offsetInEndSection": 686
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Comparisons of experimental data with predictions based upon the three inhibitory models show that product inhibition during luciferase luminescence is noncompetitive with respect to both luciferin and ATP as substrates.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/836795",
          "offsetInBeginSection": 377,
          "offsetInEndSection": 597
        }
      ],
      "id": "642f49db57b1c7a315000014",
      "type": "list",
      "body": "List the luciferase substrates"
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/33083114",
        "http://www.ncbi.nlm.nih.gov/pubmed/35760052",
        "http://www.ncbi.nlm.nih.gov/pubmed/26845852",
        "http://www.ncbi.nlm.nih.gov/pubmed/10066109"
      ],
      "snippets": [
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Transcription factors regulating both the identity and patterning of embryonic structures and the development of individual organs are often called master regulatory genes. These genes, as well as other transcription factors, are parts of signaling networks mediating cellular communication, including inductive interactions between nearby tissues.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10066109",
          "offsetInBeginSection": 386,
          "offsetInEndSection": 734
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "The transformation of normal precursors into cancer cells is an intricately regulated, multistep process. The master regulatory genes that play a crucial role in the process of organism development may also play a key role in carcinogenesis.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26845852",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 241
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "SOX genesare master regulatory genes controlling development and are fundamental to the establishment of sex determination in a multitude of organisms.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35760052",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 151
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Because a MRG can regulate the concurrent expression of several genes, its mutation often leads to major diseases.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33083114",
          "offsetInBeginSection": 215,
          "offsetInEndSection": 329
        }
      ],
      "id": "645037e557b1c7a31500008c",
      "type": "summary",
      "body": "What are master regulatory genes?"
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/29624723"
      ],
      "snippets": [
        {
          "beginSection": "title",
          "endSection": "title",
          "text": "Randomized, clinical trial of RT001: Early signals of efficacy in Friedreich\u0027s ataxia.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29624723",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 86
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "We conducted a phase I/II double-blind, comparator-controlled trial with 2 doses of RT001 in Friedreich\u0027s ataxia patients (9 subjects each cohort). ",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29624723",
          "offsetInBeginSection": 352,
          "offsetInEndSection": 500
        }
      ],
      "id": "64402bb057b1c7a315000043",
      "type": "factoid",
      "body": "In what type of clinical trial has RT001 been evaluated against Friedreich\u0027s ataxia?"
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/35394612",
        "http://www.ncbi.nlm.nih.gov/pubmed/34767470",
        "http://www.ncbi.nlm.nih.gov/pubmed/35927155"
      ],
      "snippets": [
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Inflammatory myopathies, including polymyositis (PM), dermatomyositis (DM), inclusion body myositis (IBM), necrotizing myopathy (NM), antisynthetase syndrome (ASS) and overlap myositis (OM), in short myositis, are rare diseases.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35394612",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 228
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "This review describes the clinical features, diagnosis and treatment for IIMs, namely polymyositis (PM), dermatomyositis (DM), sporadic inclusion body myositis (sIBM), immune-mediated necrotizing myopathy (IMNM), and myositis associated with antisynthetase syndrome (ASS).",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34767470",
          "offsetInBeginSection": 135,
          "offsetInEndSection": 407
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "The search strategy from the 2021 Cochrane Physical Activity review in neuromuscular disease was used, and we selected articles that included people with IIM, including Dermatomyositis (DM), Inclusion Body Myositis (IBM), Immune Mediated Necrotising Myopathy (IMNM) [also known as necrotizing autoimmune myopathy (NAM)], and Polymyositis (PM).",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35927155",
          "offsetInBeginSection": 307,
          "offsetInEndSection": 650
        }
      ],
      "id": "6450bf2557b1c7a31500008d",
      "type": "list",
      "body": "Which are the known inflammatory myopathies?"
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/35921449",
        "http://www.ncbi.nlm.nih.gov/pubmed/36260982"
      ],
      "snippets": [
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "METHODS: We conducted a phase 1 clinical trial to assess the safety and pharmacokinetics of L9LS, a next-generation antimalarial monoclonal antibody, and its protective efficacy against controlled human malaria infection in healthy adults who had never had malaria or received a vaccine for malaria.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35921449",
          "offsetInBeginSection": 165,
          "offsetInEndSection": 464
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "CONCLUSIONS: In this small trial, L9LS administered intravenously or subcutaneously protected recipients against malaria after controlled infection, without evident safety concerns.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35921449",
          "offsetInBeginSection": 2119,
          "offsetInEndSection": 2300
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "L9LS, a potent and safe antimalarial monoclonal antibody, demonstrated 88% protective efficacy against infection in a phase 1 trial in healthy adults.1 ",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36260982",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 152
        }
      ],
      "id": "63eef8d6f36125a42600000f",
      "type": "factoid",
      "body": "L9LS was developed for which disease?"
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/35381889",
        "http://www.ncbi.nlm.nih.gov/pubmed/34460113",
        "http://www.ncbi.nlm.nih.gov/pubmed/32868463",
        "http://www.ncbi.nlm.nih.gov/pubmed/31162719"
      ],
      "snippets": [
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Developmental iron deficiency (dID) models facilitate the study of specific oligodendrocyte (OL) requirements for their progression to a mature state and subsequent contribution to myelinatio",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31162719",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 191
        },
        {
          "beginSection": "title",
          "endSection": "title",
          "text": "Ontogenetic oligodendrocyte maturation through gestational iron deprivation: The road not taken.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31162719",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 96
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": " the expression levels of Hes5, Sox10, and Olig1 in dID conditions correlated with an unfavorable OL maturation profile.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31162719",
          "offsetInBeginSection": 1444,
          "offsetInEndSection": 1564
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": " the current results provide further evidence of dID impact on myelination, keeping OL away from the maturational path.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31162719",
          "offsetInBeginSection": 1572,
          "offsetInEndSection": 1691
        },
        {
          "beginSection": "title",
          "endSection": "title",
          "text": "Impaired Postnatal Myelination in a Conditional Knockout Mouse for the Ferritin Heavy Chain in Oligodendroglial Cells.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32868463",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 118
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "To define the importance of iron storage in oligodendrocyte development and function, the ferritin heavy subunit (Fth) was specifically deleted in oligodendroglial cells.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32868463",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 170
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Fth iron storage is essential for early oligodendrocyte development as well as for OPC maturation in the demyelinated adult brain.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32868463",
          "offsetInBeginSection": 2314,
          "offsetInEndSection": 2444
        },
        {
          "beginSection": "title",
          "endSection": "title",
          "text": "H-ferritin expression in astrocytes is necessary for proper oligodendrocyte development and myelination.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34460113",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 104
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": " These results indicate that Fth iron storage in astrocytes is vital for early oligodendrocyte development as well as for the remyelination of the CNS.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34460113",
          "offsetInBeginSection": 1478,
          "offsetInEndSection": 1629
        }
      ],
      "id": "6419d79c690f196b5100003b",
      "type": "yesno",
      "body": "Does iron regulate oligodendrocyte maturation?"
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/20235850",
        "http://www.ncbi.nlm.nih.gov/pubmed/32477401",
        "http://www.ncbi.nlm.nih.gov/pubmed/34605948"
      ],
      "snippets": [
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Each human, when born, has slightly different DNA sequences, which make each of us unique. The variations in DNA sequences are called genetic variants. The primary aim of genome-wide association study (GWAS) is to detect associations between genetic variants and human phenotypes.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34605948",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 280
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Genome-wide association studies (GWAS) have successfully mapped thousands of loci associated with complex traits. These associations could reveal the molecular mechanisms altered in common complex diseases and result in the identification of novel drug targets.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32477401",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 261
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Genome-wide association studies (GWAS) provide an important avenue for undertaking an agnostic evaluation of the association between common genetic variants and risk of disease. Recent advances in our understanding of human genetic variation and the technology to measure such variation have made GWAS feasible. Over the past few years a multitude of GWAS have identified and replicated many associated variants. These findings are enriching our knowledge about the genetic basis of disease and leading some to advocate using GWA study results for genetic testing. For many of the GWA study results, however, the underlying mechanisms remain unclear and the findings explain only a limited amount of heritability.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20235850",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 713
        }
      ],
      "id": "644ea46d57b1c7a31500007c",
      "type": "summary",
      "body": "What are genome-wide association studies (GWAS)?"
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/35594654"
      ],
      "snippets": [
        {
          "beginSection": "title",
          "endSection": "title",
          "text": "Design and synthesis of proteolysis targeting chimeras (PROTACs) as an EGFR degrader based on CO-1686.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35594654",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 102
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "The emerging technology proteolysis targeting chimera (PROTAC) could be an alternative strategy to overcome these problems. ",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35594654",
          "offsetInBeginSection": 241,
          "offsetInEndSection": 365
        }
      ],
      "id": "64121f44201352f04a000037",
      "type": "factoid",
      "body": "What does PROTACs stand for?"
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/24299589"
      ],
      "snippets": [
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Leigh syndrome (LS), or subacute necrotizing encephalomyelopathy, is the most common childhood mitochondrial encephalopathy, accounting for more than 50% of cases in this age group. Its estimated incidence is 1:40,000 - 1:77,000 liveborn infants a year.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24299589",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 253
        }
      ],
      "id": "6451029f57b1c7a315000094",
      "type": "factoid",
      "body": "What is the incidence of Leigh syndrome?"
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/29162267",
        "http://www.ncbi.nlm.nih.gov/pubmed/10347389"
      ],
      "snippets": [
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "It is a serious threat to prehospital patients and especially injured patients, since it can induce a vicious cycle of the synergistic effects of hypothermia, acidosis and coagulopathy; referred to as the trauma triad of death. ",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29162267",
          "offsetInBeginSection": 143,
          "offsetInEndSection": 371
        },
        {
          "beginSection": "title",
          "endSection": "title",
          "text": "The trauma triad of death: hypothermia, acidosis, and coagulopathy.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10347389",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 67
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "The \"new\" golden hour may well be the time in the operating room before the patient reaches the physiologic limit, defined as the onset of the triad: hypothermia, acidosis and coagulopathy.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10347389",
          "offsetInBeginSection": 665,
          "offsetInEndSection": 854
        }
      ],
      "id": "64041260201352f04a000013",
      "type": "list",
      "body": "What are features of the The Trauma Triad of Death?"
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/34016519",
        "http://www.ncbi.nlm.nih.gov/pubmed/33608105",
        "http://www.ncbi.nlm.nih.gov/pubmed/35671092",
        "http://www.ncbi.nlm.nih.gov/pubmed/35672195",
        "http://www.ncbi.nlm.nih.gov/pubmed/35985885",
        "http://www.ncbi.nlm.nih.gov/pubmed/36254878"
      ],
      "snippets": [
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Surgeons treating advanced carcinoma of the tongue with total glossectomy face many conflicts in view of the morbidity and poor functional and survival outcomes following surgery. I",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34016519",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 181
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Ablation of a tongue tumor leaves defects that can be either surgically reconstructed or replaced by a prosthesis to help recreate normalcy and balance in the oral cavity. This clinical report describes a prosthetic design to rehabilitate a patient after a total glossectomy.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33608105",
          "offsetInBeginSection": 136,
          "offsetInEndSection": 411
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Wide variation in negotiated surgical prices was identified. Across-center ratios ranged from 6.2 (partial glossectomy without primary closure) to 22.8 (excision of tongue lesion without closure).",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35671092",
          "offsetInBeginSection": 488,
          "offsetInEndSection": 684
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "The aim of this study was to test the non-inferiority of the contralateral submental island flap (CSIF) compared with primary closure (PC) regarding local recurrence after partial glossectomy in patients with oral tongue squamous cell carcinoma (OTSCC). T",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35672195",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 255
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Locally advanced tongue or tongue base cancer is recommended to be treated by radical resection that is usually detrimental to physiological functions. This study reports the efficacy and treatment outcome of the patients who had received total glossectomy and laryngeal suspension without lip-split mandibulotomy ",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35985885",
          "offsetInBeginSection": 20,
          "offsetInEndSection": 334
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "To evaluate potential interactions and compensatory mechanisms of subjectively impaired taste function with ortho- and retronasal olfaction after glossectomy.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36254878",
          "offsetInBeginSection": 11,
          "offsetInEndSection": 169
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": " In this cross-sectional pilot study, chemosensory functions were assessed in 25 patients with tongue carcinomas after glossectomy.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36254878",
          "offsetInBeginSection": 182,
          "offsetInEndSection": 313
        }
      ],
      "id": "6431f74057b1c7a31500001a",
      "type": "summary",
      "body": "What is a glossectomy?"
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/35583646",
        "http://www.ncbi.nlm.nih.gov/pubmed/34870779",
        "http://www.ncbi.nlm.nih.gov/pubmed/33605616",
        "http://www.ncbi.nlm.nih.gov/pubmed/32533130"
      ],
      "snippets": [
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Epigenetic modifications may constitute changes in DNA methylation, histone modifications (methylation, acetylation etc), and changes in non-coding RNA, leading to an altered gene expression profile.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35583646",
          "offsetInBeginSection": 437,
          "offsetInEndSection": 636
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Epigenetic modifications viz. DNA methylation, histone modifications, and RNA-based alterations play a crucial role in the development of cardiovascular diseases.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34870779",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 162
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Major epigenetic modifications are DNA methylation, histone modification, chromatin remodeling as well as the noncoding RNAs.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33605616",
          "offsetInBeginSection": 275,
          "offsetInEndSection": 400
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Eukaryotic gene expression is regulated not only by genomic enhancers and promoters, but also by covalent modifications added to both chromatin and RNAs. Whereas cellular gene expression may be either enhanced or inhibited by specific epigenetic modifications deposited on histones (in particular, histone H3), these epigenetic modifications can also repress viral gene expression, potentially functioning as a potent antiviral innate immune response in DNA virus-infected cells.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32533130",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 479
        }
      ],
      "id": "644eb55457b1c7a315000081",
      "type": "list",
      "body": "What are some examples of epigenetic modifications?"
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/35651781"
      ],
      "snippets": [
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "In the United States, zanubrutinib, a next-generation BTK inhibitor, has been approved for treating adults with mantle cell lymphoma who have received at least one prior therapy, for adults with Waldenström macroglobulinemia, and for adults with relapsed or refractory marginal zone lymphoma who have received at least one anti-CD20-based therapy. B",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35651781",
          "offsetInBeginSection": 543,
          "offsetInEndSection": 892
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "To reduce these side effects, zanubrutinib, a next-generation BTK inhibitor, was designed to block BTK more specifically than ibrutinib.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35651781",
          "offsetInBeginSection": 2451,
          "offsetInEndSection": 2587
        }
      ],
      "id": "6432f5f257b1c7a31500001c",
      "type": "factoid",
      "body": "What does Zanubrutinib inhibit?"
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/31467149"
      ],
      "snippets": [
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Friedreich\u0027s ataxia is classically considered a disease with onset in the first or second decade. However, late-onset (age of onset 25-39 years) and very-late-onset (age of onset \u003e40 years) forms do occur rarely.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31467149",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 212
        }
      ],
      "id": "6450f02257b1c7a315000091",
      "type": "list",
      "body": "Which are the types of Friedreich\u0027s Ataxia based on onset age?"
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/35671774",
        "http://www.ncbi.nlm.nih.gov/pubmed/36110891",
        "http://www.ncbi.nlm.nih.gov/pubmed/32035020"
      ],
      "snippets": [
        {
          "beginSection": "title",
          "endSection": "title",
          "text": "Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive, HER2-negative breast cancer (FAKTION): overall survival, updated progression-free survival, and expanded biomarker analysis from a randomised, phase 2 trial.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35671774",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 301
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "INTERPRETATION: Updated FAKTION data showed that capivasertib addition to fulvestrant extends the survival of participants with aromatase inhibitor-resistant ER-positive, HER2-negative advanced breast cancer. ",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35671774",
          "offsetInBeginSection": 4240,
          "offsetInEndSection": 4449
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Similarly, there was an overall survival benefit in the FAKTION study with capivasertib. ",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36110891",
          "offsetInBeginSection": 866,
          "offsetInEndSection": 955
        },
        {
          "beginSection": "title",
          "endSection": "title",
          "text": "Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive breast cancer (FAKTION): a multicentre, randomised, controlled, phase 2 trial.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32035020",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 221
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "The FAKTION trial investigated whether the addition of capivasertib to fulvestrant improved progression-free survival in patients with aromatase inhibitor-resistant advanced breast cancer.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32035020",
          "offsetInBeginSection": 130,
          "offsetInEndSection": 318
        }
      ],
      "id": "6402bd7c201352f04a000006",
      "type": "list",
      "body": "Which drugs were tested in the FAKTION trial?"
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/14961259",
        "http://www.ncbi.nlm.nih.gov/pubmed/16025102",
        "http://www.ncbi.nlm.nih.gov/pubmed/16443930",
        "http://www.ncbi.nlm.nih.gov/pubmed/18577207"
      ],
      "snippets": [
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Gene knock-down technology using antisense molecules has many applications for studying gene function, disrupting undesirable genetic traits, as well as providing effective therapy for a number of viral diseases. ",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/14961259",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 213
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "The largest gene knock-down experiments performed to date have used multiple short interfering/short hairpin (si/sh)RNAs per gene.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16025102",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 130
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Short interfering RNAs (siRNAs) have been gaining popularity as the gene knock-down tool of choice by many researchers because of the clean nature of their workings as well as the technical simplicity and cost efficiency in their applications. ",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16443930",
          "offsetInBeginSection": 12,
          "offsetInEndSection": 256
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Gene knock down by RNAi is a highly effective approach to silence gene expression in experimental as well as therapeutic settings.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18577207",
          "offsetInBeginSection": 12,
          "offsetInEndSection": 142
        }
      ],
      "id": "64184949690f196b51000039",
      "type": "summary",
      "body": "Explain gene knock-down."
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/33923658",
        "http://www.ncbi.nlm.nih.gov/pubmed/25836925",
        "http://www.ncbi.nlm.nih.gov/pubmed/24617759"
      ],
      "snippets": [
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "RNA splicing is a critical step in the maturation of precursor mRNA (pre-mRNA) by removing introns and exons. The combination of inclusion and exclusion of introns and exons in pre-mRNA can generate vast diversity in mature mRNA from a limited number of genes.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33923658",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 260
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Transport of messenger RNA (mRNA) from the nucleus to the cytoplasm is an essential step of eukaryotic gene expression. In the cell nucleus, a precursor mRNA undergoes a series of processing steps, including capping at the 5\u0027 ends, splicing and cleavage/polyadenylation at the 3\u0027 ends.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25836925",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 285
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Messenger RNA precursors (pre-mRNAs) are produced as the nascent transcripts of RNA polymerase II (Pol II) in eukaryotes and must undergo extensive maturational processing, including 5\u0027-end capping, splicing, and 3\u0027-end cleavage and polyadenylation.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24617759",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 249
        }
      ],
      "id": "644ea41957b1c7a31500007b",
      "type": "list",
      "body": "What are the necessary steps for the transition from a precursor mRNA to a mature\nmRNA?"
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/36255686"
      ],
      "snippets": [
        {
          "beginSection": "title",
          "endSection": "title",
          "text": "Cabotegravir Extended-Release Injectable Suspension: A Review in HIV-1 Pre-Exposure Prophylaxis.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36255686",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 96
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Cabotegravir extended-release (ER) injectable suspension (Apretude™) is the first long-acting injectable option to be approved for HIV-1 pre-exposure prophylaxis (PrEP). ",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36255686",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 170
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Cabotegravir ER injectable suspension is indicated in the USA for PrEP to reduce the risk of sexually acquired HIV-1 infection in at-risk adults and adolescents weighing ≥ 35 kg who have a negative HIV-1 test prior to initiation.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36255686",
          "offsetInBeginSection": 465,
          "offsetInEndSection": 694
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "With its convenient, less-frequent dosing schedule and its long-acting formulation enabling intramuscular administration, cabotegravir ER injectable suspension represents a novel and efficacious alternative to daily oral PrEP.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36255686",
          "offsetInBeginSection": 1086,
          "offsetInEndSection": 1312
        }
      ],
      "id": "6440420857b1c7a315000050",
      "type": "factoid",
      "body": "What is Apretude used for?"
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/35284988",
        "http://www.ncbi.nlm.nih.gov/pubmed/33090613",
        "http://www.ncbi.nlm.nih.gov/pubmed/35466947",
        "http://www.ncbi.nlm.nih.gov/pubmed/36335004",
        "http://www.ncbi.nlm.nih.gov/pubmed/34878390",
        "http://www.ncbi.nlm.nih.gov/pubmed/35996994",
        "http://www.ncbi.nlm.nih.gov/pubmed/14704958"
      ],
      "snippets": [
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "SMA with a clinical diagnosis of SMA types 1, 2, or 3",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35284988",
          "offsetInBeginSection": 324,
          "offsetInEndSection": 377
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": " In phase 2/3 clinical trials, risdiplam significantly improved motor function in infants with SMA type 1 and in patients aged 2-25 years with SMA types 2 or 3.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35284988",
          "offsetInBeginSection": 591,
          "offsetInEndSection": 751
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Adulthood-onset SMA (SMA type 4) is rare, with few isolated cases reported.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33090613",
          "offsetInBeginSection": 190,
          "offsetInEndSection": 265
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Twenty patients with SMA type 4 were identified in a Brazilian cohort of 227 patients with SMA. ",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33090613",
          "offsetInBeginSection": 643,
          "offsetInEndSection": 739
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "This study represents the largest cohort of patients with SMA type 4 and provides functional, genetic, radiological and neurophysiological features ",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33090613",
          "offsetInBeginSection": 1675,
          "offsetInEndSection": 1823
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Adolescent and adult patients with SMA types 3 and 4",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35466947",
          "offsetInBeginSection": 295,
          "offsetInEndSection": 347
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "We found no evidence for the contribution of motor unit and capillary recruitment capacity of the upper arm muscles in adolescent and adult patients with SMA types 3 and 4 as primary limiting factors to premature fatigue during execution of a maximal arm-cycling task.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35466947",
          "offsetInBeginSection": 1632,
          "offsetInEndSection": 1900
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "We report a long-term follow-up in adolescent and adult patients with SMA types 1 and 2.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36335004",
          "offsetInBeginSection": 262,
          "offsetInEndSection": 350
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Nusinersen-treated patients with SMA types 1 and 2 between 2017 and 2022 were retrospectively reviewed. ",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36335004",
          "offsetInBeginSection": 359,
          "offsetInEndSection": 463
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Seven patients with SMA (type 1, 1; type 2, 6) with a median age of 23 (range, 12-40)years were treated with nusinersen for 3.55 (1.78-4.53)years.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36335004",
          "offsetInBeginSection": 922,
          "offsetInEndSection": 1068
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "On October 1st, 666 patients have been enrolled (357 children and 309 adults) by 44 out of 51 open centers of the national network (FILNEMUS) with: 150 type 1 (22%); 278 type 2 (42%), 232 type 3 (35%) and 4 type 4 (1%) respectively.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34878390",
          "offsetInBeginSection": 778,
          "offsetInEndSection": 1010
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "The identification of the underlying gene defects for familial ALS, spinal muscular atrophy (SMA), and spinal muscular atrophy with respiratory distress (SMARD) has pointed to distinct pathophysiological mechanisms that are responsible for the various forms of the disease. ",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/14704958",
          "offsetInBeginSection": 122,
          "offsetInEndSection": 396
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Interestingly, UBA1 mutations can also cause infantile-onset X-linked spinal muscular atrophy (XL-SMA).",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35996994",
          "offsetInBeginSection": 1046,
          "offsetInEndSection": 1149
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "The mutation identified here and the XL-SMA causative mutations were shown to affect amino acids positioned in the vicinity of UBA1\u0027s ATP binding site and to cause structural changes.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35996994",
          "offsetInBeginSection": 1150,
          "offsetInEndSection": 1333
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "The contribution of this same gene to the etiology of XL-SMA is discussed.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35996994",
          "offsetInBeginSection": 1515,
          "offsetInEndSection": 1589
        }
      ],
      "id": "64463a5057b1c7a315000064",
      "type": "list",
      "body": "What are the types of Spinal Muscular Atrophy?"
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/35779372",
        "http://www.ncbi.nlm.nih.gov/pubmed/35570581",
        "http://www.ncbi.nlm.nih.gov/pubmed/36001711",
        "http://www.ncbi.nlm.nih.gov/pubmed/35869335",
        "http://www.ncbi.nlm.nih.gov/pubmed/35378683"
      ],
      "snippets": [
        {
          "beginSection": "title",
          "endSection": "title",
          "text": "Outcomes of Ublituximab compared to Teriflunomide for relapsing multiple sclerosis: A meta-analysis.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35779372",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 100
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Ublituximab is an anti-CD20 antibody that immunomodulates B-cells for relapsing multiple sclerosis (MS).",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35779372",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 104
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": " In the second part of the review, we summarize medications that have targeted B cells in patients with MS and their current position in the therapeutic armamentarium based on clinical trials and real-world data. Covered therapeutic strategies include the targeting of surface molecules such as CD20 (rituximab, ocrelizumab, ofatumumab, ublituximab) and CD19 (inebilizumab), and molecules necessary for B-cell activation such as B cell activating factor (BAFF) (belimumab) and Bruton\u0027s Tyrosine Kinase (BTK) (evobrutinib).",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35570581",
          "offsetInBeginSection": 826,
          "offsetInEndSection": 1348
        },
        {
          "beginSection": "title",
          "endSection": "title",
          "text": "Ublituximab versus Teriflunomide in Relapsing Multiple Sclerosis.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36001711",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 65
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Ublituximab is being evaluated for the treatment of relapsing multiple sclerosis.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36001711",
          "offsetInBeginSection": 126,
          "offsetInEndSection": 207
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "CONCLUSIONS: Among participants with relapsing multiple sclerosis, ublituximab resulted in lower annualized relapse rates and fewer brain lesions on MRI than teriflunomide over a period of 96 weeks but did not result in a significantly lower risk of worsening of disability. ",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36001711",
          "offsetInBeginSection": 1973,
          "offsetInEndSection": 2248
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "The glycoengineered antibody ublituximab is the next anti-CD20 therapy about to be approved. ",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35869335",
          "offsetInBeginSection": 815,
          "offsetInEndSection": 908
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "On the other hand, the anti-CD52 monoclonal antibody alemtuzumab and the anti-CD20 monoclonal antibodies rituximab, ocrelizumab, ofatumumab, and ublituximab work via eliminating selected pathogenic cell populations. ",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35378683",
          "offsetInBeginSection": 707,
          "offsetInEndSection": 923
        }
      ],
      "id": "63eef4f5f36125a42600000b",
      "type": "factoid",
      "body": "What disease is treated with Ublituximab?"
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/3830522"
      ],
      "snippets": [
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Palmar erythema (\"liver palms\") was seen in 32/100 consecutive patients with classical rheumatoid arthritis and in 10/100 patients with various other internal diseases (p less than 0.001",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/3830522",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 186
        }
      ],
      "id": "640c842f201352f04a000025",
      "type": "factoid",
      "body": "What is Palmar Erythema?"
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/21734376",
        "http://www.ncbi.nlm.nih.gov/pubmed/26216216"
      ],
      "snippets": [
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Epigenetics is defined as heritable changes in gene expression that are, unlike mutations, not attributable to alterations in the sequence of DNA. The predominant epigenetic mechanisms are DNA methylation, modifications to chromatin, loss of imprinting and non-coding RNA.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21734376",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 272
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Genome-wide association studies of complex physiological traits and diseases consistently found that associated genetic factors, such as allelic polymorphisms or DNA mutations, only explained a minority of the expected heritable fraction. This discrepancy is known as \"missing heritability\", and its underlying factors and molecular mechanisms are not established. Epigenetic programs may account for a significant fraction of the \"missing heritability.\" Epigenetic modifications, such as DNA methylation and chromatin assembly states, reflect the high plasticity of the genome and contribute to stably alter gene expression without modifying genomic DNA sequences.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26216216",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 665
        }
      ],
      "id": "644efd5157b1c7a315000086",
      "type": "yesno",
      "body": "Are epigenetic changes heritable?"
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/35118122"
      ],
      "snippets": [
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Trichotillomania requires a comprehensive treatment plan and interdisciplinary approach. ",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35118122",
          "offsetInBeginSection": 581,
          "offsetInEndSection": 670
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Behavioral therapy has been used with success in the treatment of trichotillomania, but not all patients are willing or able to comply with this treatment strategy. Pharmacotherapy can be necessary, especially in adolescents and adult patients. Options include tricyclic antidepressants, selective serotonin reuptake inhibitors, and glutamate-modulating agents. Glutamate-modulating agents such as N-acetylcysteine are a good first-line option due to significant benefits and low risk of side effects.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35118122",
          "offsetInBeginSection": 769,
          "offsetInEndSection": 1270
        }
      ],
      "id": "6414c1d0690f196b51000004",
      "type": "summary",
      "body": "What is the treatment for trichotillomania?"
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/33805441",
        "http://www.ncbi.nlm.nih.gov/pubmed/34225694"
      ],
      "snippets": [
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Oculopharyngeal muscular dystrophy (OPMD) is a late-onset intractable myopathy, characterized by slowly progressive ptosis, dysphagia, and proximal limb weakness. It is caused by the abnormal expansion of the alanine-encoding (GCN)n trinucleotide repeat in the exon 1 of the polyadenosine (poly[A]) binding protein nuclear 1 gene (11-18 repeats in OPMD instead of the normal 10 repeats).",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33805441",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 387
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "A common cause of OPMD is the short expansion of a GCG or GCA trinucleotide repeat in PABPN1 gene.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34225694",
          "offsetInBeginSection": 179,
          "offsetInEndSection": 277
        }
      ],
      "id": "64468b0757b1c7a315000070",
      "type": "factoid",
      "body": "What is the cause of Oculopharyngeal Muscular Dystrophy (OPMD)?"
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/35172056",
        "http://www.ncbi.nlm.nih.gov/pubmed/36401806",
        "http://www.ncbi.nlm.nih.gov/pubmed/33720995"
      ],
      "snippets": [
        {
          "beginSection": "title",
          "endSection": "title",
          "text": "EDP-938, a Respiratory Syncytial Virus Inhibitor, in a Human Virus Challenge.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35172056",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 77
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "EDP-938, a nonfusion replication inhibitor of RSV, acts by modulating the viral nucleoprotein.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35172056",
          "offsetInBeginSection": 158,
          "offsetInEndSection": 252
        },
        {
          "beginSection": "title",
          "endSection": "title",
          "text": "EDP-938, a new antiviral with inhibitory activity against the nucleoprotein of the respiratory syncytial virus.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36401806",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 111
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "EDP-938 has shown high efficacy against RSV. ",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36401806",
          "offsetInBeginSection": 541,
          "offsetInEndSection": 586
        },
        {
          "beginSection": "title",
          "endSection": "title",
          "text": "EDP-938, a novel nucleoprotein inhibitor of respiratory syncytial virus, demonstrates potent antiviral activities in vitro and in a non-human primate model.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33720995",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 156
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "EDP-938 is a novel non-fusion replication inhibitor of respiratory syncytial virus (RSV). ",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33720995",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 90
        }
      ],
      "id": "63f0494cf36125a426000028",
      "type": "factoid",
      "body": "Which viral disease can be treated with EDP-938?"
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/28643244",
        "http://www.ncbi.nlm.nih.gov/pubmed/29571563",
        "http://www.ncbi.nlm.nih.gov/pubmed/30917623"
      ],
      "snippets": [
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "durvalumab (Imfinzi™; AstraZeneca) is a fully human monoclonal antibody that blocks programmed cell death ligand-1 binding to its receptors (PD-1 and CD80),",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28643244",
          "offsetInBeginSection": 12,
          "offsetInEndSection": 168
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "durvalumab (IMFINZI®, Astra-Zeneca",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29571563",
          "offsetInBeginSection": 369,
          "offsetInEndSection": 403
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "durvalumab (Imfinzi®)",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30917623",
          "offsetInBeginSection": 375,
          "offsetInEndSection": 396
        }
      ],
      "id": "640ddbe9201352f04a000027",
      "type": "factoid",
      "body": "What is the generic name for Imfinzi?"
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/26110128",
        "http://www.ncbi.nlm.nih.gov/pubmed/21990031",
        "http://www.ncbi.nlm.nih.gov/pubmed/14744434"
      ],
      "snippets": [
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "The cell cycle (or cell-division cycle) is a series of events that take place in a cell, leading to its division and duplication. Cell division requires cell cycle checkpoints (CPs) that are used by the cell to both monitor and regulate the progress of the cell cycle. Tumor-suppressor genes (TSGs) or antioncogenes are genes that protect the cell from a single event or multiple events leading to cancer. When these genes mutate, the cell can progress to a cancerous state.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26110128",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 474
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Deregulation of the cell cycle underlies the aberrant cell proliferation that characterizes cancer and loss of cell cycle checkpoint control promotes genetic instability. During the past two decades, cancer genetics has shown that hyperactivating mutations in growth signalling networks, coupled to loss of function of tumour suppressor proteins, drives oncogenic proliferation.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21990031",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 378
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": " We now recognize that tumor suppressor genes regulate diverse cellular activities, including cell cycle checkpoint responses, detection and repair of DNA damage, protein ubiquitination and degradation, mitogenic signaling, cell specification, differentiation and migration, and tumor angiogenesis.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/14744434",
          "offsetInBeginSection": 439,
          "offsetInEndSection": 737
        }
      ],
      "id": "644e81fa57b1c7a315000079",
      "type": "factoid",
      "body": "What are negative cell-cycle regulators that can cause cancer when mutated called?"
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/28235882"
      ],
      "snippets": [
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "On September 4, 2014, the FDA approved pembrolizumab (KEYTRUDA; Merck Sharp \u0026 Dohme Corp.) with a recommended dose of 2 mg/kg every 3 weeks by intravenous infusion for the treatment of patients with unresectable or metastatic melanoma who have progressed following treatment with ipilimumab and, if BRAF V600 mutation positive, a BRAF inhibitor. ",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28235882",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 346
        }
      ],
      "id": "6415c7fb690f196b51000016",
      "type": "factoid",
      "body": "When was Keytruda approved for the treatment of melanoma?"
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/36401050"
      ],
      "snippets": [
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Oculopharyngeal muscular dystrophy (OPMD) is a late-onset rare muscle disease affecting approximately 1 in 80,000 individuals worldwide. However, it can affect as much as 1:600 individuals in some populations due to a strong founder effect. ",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36401050",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 241
        }
      ],
      "id": "64468e0d57b1c7a315000071",
      "type": "factoid",
      "body": "What is the incidence of Oculopharyngeal Muscular Dystrophy (OPMD)?"
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/34932533"
      ],
      "snippets": [
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Most commonly affecting males between 50 and 70 years of age, Clinically, the Mackler triad is vomiting, severe chest pain, and subcutaneous cervical emphysema.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34932533",
          "offsetInBeginSection": 175,
          "offsetInEndSection": 335
        }
      ],
      "id": "64041355201352f04a000014",
      "type": "list",
      "body": "What are features of the Mackler’s Triad?"
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/12049630",
        "http://www.ncbi.nlm.nih.gov/pubmed/14633596",
        "http://www.ncbi.nlm.nih.gov/pubmed/18218922"
      ],
      "snippets": [
        {
          "beginSection": "title",
          "endSection": "title",
          "text": "Human tastin, a proline-rich cytoplasmic protein, associates with the microtubular cytoskeleton.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12049630",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 96
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Tastin was originally identified as an accessory protein for trophinin, a cell adhesion molecule that potentially mediates the initial attachment of the human embryo to the uterine epithelium. H",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12049630",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 194
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Trophinin, tastin, and bystin have been identified as molecules potentially involved in human embryo implantation",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/14633596",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 113
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Tastin was previously characterized as an accessory protein for cell adhesion that participates in early embryo implantation",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18218922",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 124
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Here, we report that tastin is also required for spindle assembly during mitosis. Tastin protein levels peaked in the G(2)/M phase and abruptly declined after cell division",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18218922",
          "offsetInBeginSection": 126,
          "offsetInEndSection": 298
        }
      ],
      "id": "641373fc201352f04a000040",
      "type": "summary",
      "body": "What is Tastin?"
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/26216216",
        "http://www.ncbi.nlm.nih.gov/pubmed/21734376",
        "http://www.ncbi.nlm.nih.gov/pubmed/33781317"
      ],
      "snippets": [
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Epigenetic modifications, such as DNA methylation and chromatin assembly states, reflect the high plasticity of the genome and contribute to stably alter gene expression without modifying genomic DNA sequences.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26216216",
          "offsetInBeginSection": 455,
          "offsetInEndSection": 665
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Epigenetics is defined as heritable changes in gene expression that are, unlike mutations, not attributable to alterations in the sequence of DNA.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21734376",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 146
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Epigenetic changes are inheritable modifications that can modify the gene expression without changing the DNA sequence. The most common epigenetic alternations consist of DNA methylation and histone modifications.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33781317",
          "offsetInBeginSection": 125,
          "offsetInEndSection": 338
        }
      ],
      "id": "644efd2c57b1c7a315000085",
      "type": "yesno",
      "body": "Do epigenetic changes change the DNA sequence?"
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/21426252"
      ],
      "snippets": [
        {
          "beginSection": "title",
          "endSection": "title",
          "text": "hC1INH: a new drug for the treatment of attacks in hereditary angioedema caused by C1-inhibitor deficiency.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21426252",
          "offsetInBeginSection": 1,
          "offsetInEndSection": 108
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Recombinant human C1 esterase inhibitor (rhC1INH) (Ruconest(®), Pharming) is a new drug developed for the relief of symptoms occurring in patients with angioedema due to C1-inhibitor deficiency.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21426252",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 194
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Similar to the purified C1-inhibitor derived from human plasma, the therapeutic efficacy of rhC1INH results from its ability to block the actions of enzymes belonging to the overactivated bradykinin-forming pathway, at multiple locations. ",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21426252",
          "offsetInBeginSection": 306,
          "offsetInEndSection": 545
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Dose-ranging efficacy studies established 50 U/kg as the recommended dose, and demonstrated the effectiveness of this agent in all localizations of hereditary angioedema attacks.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21426252",
          "offsetInBeginSection": 715,
          "offsetInEndSection": 893
        }
      ],
      "id": "6433020c57b1c7a315000023",
      "type": "summary",
      "body": "What is Ruconest?"
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/36143200",
        "http://www.ncbi.nlm.nih.gov/pubmed/35511862",
        "http://www.ncbi.nlm.nih.gov/pubmed/34603008"
      ],
      "snippets": [
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Motor neurons (MNs) are specialized neurons responsible for muscle contraction that specifically degenerate in motor neuron diseases (MNDs), such as amyotrophic lateral sclerosis (ALS), spinal and bulbar muscular atrophy (SBMA), and spinal muscular atrophy (SMA). ",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34603008",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 264
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Spinal muscular atrophy (SMA), spinal and bulbar muscular atrophy (SBMA), hereditary spastic paraplegia (HSP), and amyotrophic lateral sclerosis (ALS) are all MNDs",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35511862",
          "offsetInBeginSection": 449,
          "offsetInEndSection": 612
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Amyotrophic Lateral Sclerosis (ALS), Spinal Bulbar Muscular Atrophy (SBMA), and Spinal Muscular Atrophy (SMA) are motor neuron diseases (MNDs) characterised by progressive motor neuron degeneration, weakness and muscular atrophy.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36143200",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 229
        }
      ],
      "id": "6446ac0b57b1c7a315000072",
      "type": "list",
      "body": "Which are the motor neuron diseases?"
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/35294812",
        "http://www.ncbi.nlm.nih.gov/pubmed/36172291"
      ],
      "snippets": [
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "BACKGROUND: Hereditary angioedema is characterized by recurrent and unpredictable swellings that are disabling and potentially fatal. Selective inhibition of plasma prekallikrein production by antisense oligonucleotide treatment (donidalorsen) may reduce the frequency of attacks and the burden of disease.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35294812",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 306
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "CONCLUSIONS: Among patients with hereditary angioedema, donidalorsen treatment resulted in a significantly lower rate of angioedema attacks than placebo in this small, phase 2 trial.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35294812",
          "offsetInBeginSection": 1698,
          "offsetInEndSection": 1880
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Investigational therapies, including the activated factor XII inhibitor garadacimab and an antisense oligonucleotide targeting plasma prekallikrein messenger RNA (donidalorsen), have shown promise as long-term prophylaxis. Given the requirement of lifelong management for HAE, further research is needed to determine how best to individualize optimal treatments for each patient.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36172291",
          "offsetInBeginSection": 2231,
          "offsetInEndSection": 2610
        }
      ],
      "id": "63f04716f36125a426000025",
      "type": "factoid",
      "body": "Donidalorsen was tested for which disease?"
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/33991255",
        "http://www.ncbi.nlm.nih.gov/pubmed/35551087",
        "http://www.ncbi.nlm.nih.gov/pubmed/35547461",
        "http://www.ncbi.nlm.nih.gov/pubmed/35551628",
        "http://www.ncbi.nlm.nih.gov/pubmed/35689538",
        "http://www.ncbi.nlm.nih.gov/pubmed/35585996",
        "http://www.ncbi.nlm.nih.gov/pubmed/34690074",
        "http://www.ncbi.nlm.nih.gov/pubmed/35963982",
        "http://www.ncbi.nlm.nih.gov/pubmed/35353437",
        "http://www.ncbi.nlm.nih.gov/pubmed/35955999",
        "http://www.ncbi.nlm.nih.gov/pubmed/34904748"
      ],
      "snippets": [
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Therapeutic plasma exchange (TPE) is the most common modality employed with the rationale of rapid reduction of a pathogenic substance distributed primarily in the intravascular compartmen",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33991255",
          "offsetInBeginSection": 122,
          "offsetInEndSection": 310
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Though therapeutic apheresis modalities are employed frequently in children with kidney disease, most experiences are extrapolated from adult studies. International and national registries need to be established to elucidate the role of apheresis modalities in children with kidney disease.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33991255",
          "offsetInBeginSection": 766,
          "offsetInEndSection": 1056
        },
        {
          "beginSection": "title",
          "endSection": "title",
          "text": "Rescuing Cancer Immunity by Plasma Exchange in Metastatic Melanoma (ReCIPE-M1)",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35551087",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 78
        },
        {
          "beginSection": "title",
          "endSection": "title",
          "text": "Fulminant Hepatic Failure in Dengue Fever Without Plasma Leakage: A Case Report",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35547461",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 79
        },
        {
          "beginSection": "title",
          "endSection": "title",
          "text": "Clinical and biochemical endpoints and predictors of response to plasma exchange in septic shock",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35551628",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 96
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Recently, a randomized controlled trial (RCT) demonstrated rapid but individually variable hemodynamic improvement with therapeutic plasma exchange (TPE) in patients with septic shock.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35551628",
          "offsetInBeginSection": 12,
          "offsetInEndSection": 196
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Thrombotic thrombocytopenic purpura (TTP) is becoming a curable disease with the introduction of therapeutic plasma exchange (TPE).",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35689538",
          "offsetInBeginSection": 14,
          "offsetInEndSection": 145
        },
        {
          "beginSection": "title",
          "endSection": "title",
          "text": "Role of Therapeutic Plasmapheresis in SARS-CoV-2 Induced Cytokine Release Syndrome: A",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35585996",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 85
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Background: Cytokine release syndrome (CRS) significantly contributes to the pathophysiology and progression of COVID-19. It is speculated that therapeutic plasma exchange (TPE) can dampen CRS via elimination of pathogenic cytokines.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35585996",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 233
        },
        {
          "beginSection": "title",
          "endSection": "title",
          "text": "Successful therapeutic plasma exchange in a case with extremely severe hypertriglyceridemia secondary to diabetic ketoacidosis concomitant with type IX glycogen storage diseas",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34690074",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 175
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Therapeutic plasma exchange (TPE) is a treatment option to reduce thyroid hormones",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35963982",
          "offsetInBeginSection": 9,
          "offsetInEndSection": 91
        },
        {
          "beginSection": "title",
          "endSection": "title",
          "text": "herapeutic plasma exchange in hyperthyroidism prior to surgery",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35963982",
          "offsetInBeginSection": 1,
          "offsetInEndSection": 63
        },
        {
          "beginSection": "title",
          "endSection": "title",
          "text": "Therapeutic plasma exchange for optic neuritis attacks in patients with neuromyelitis optica spectrum disorders.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35353437",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 112
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Optic neuritis (ON) causes several sequela. Aggressive treatment with plasma exchange (TPE) is an option",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35353437",
          "offsetInBeginSection": 12,
          "offsetInEndSection": 116
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": " We recruited adults with ON in neuromyelitis optica spectrum disorders (NMOSD) patients treated with TPE. ",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35353437",
          "offsetInBeginSection": 188,
          "offsetInEndSection": 295
        },
        {
          "beginSection": "title",
          "endSection": "title",
          "text": "Total Plasma Exchange in Neuromuscular Junction Disorders-",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35955999",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 58
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Total plasma exchange (TPE) has proven efficacy in NJD",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35955999",
          "offsetInBeginSection": 246,
          "offsetInEndSection": 300
        },
        {
          "beginSection": "title",
          "endSection": "title",
          "text": "Immunoadsorption and plasma exchange-Efficient treatment options for neurological autoimmune diseases.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34904748",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 102
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Therapeutic plasma exchange (TPE) and immunoadsorption (IA) are first or second line treatment options in patients with neurological autoimmune diseases, including multiple sclerosis, neuromyelitis optica spectrum disorders (NMSOD), chronic inflammatory demyelinating polyneuropathy, acute inflammatory demyelinating polyradiculoneuropathy (Guillain-Barré syndrome), and autoimmune encephalitis",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34904748",
          "offsetInBeginSection": 12,
          "offsetInEndSection": 406
        }
      ],
      "id": "641dc49b690f196b51000042",
      "type": "list",
      "body": "Treatment with plasma exchange (TPE) is used for what diseases"
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/34367115",
        "http://www.ncbi.nlm.nih.gov/pubmed/31719176"
      ],
      "snippets": [
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "The lac operon is one of the best known gene regulatory circuits and constitutes a landmark example of how bacteria tune their metabolism to nutritional conditions. It is nearly ubiquitous in Escherichia coli strains justifying the use of its phenotype, the ability to consume lactose, for species identification.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34367115",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 313
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Transcription of bacterial genes is controlled by the coordinated action of cis- and trans-acting regulators. The activity and mode of action of these regulators can reflect different requirements for gene products in different environments. A well-studied example is the regulatory function that integrates the environmental availability of glucose and lactose to control the Escherichia colilac operon. Most studies of lac operon regulation have focused on a few closely related strains.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31719176",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 489
        }
      ],
      "id": "644ec7fe57b1c7a315000082",
      "type": "factoid",
      "body": "What are the proteins that are necessary for the use of lactose in E. coli collectively called?"
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/34346508"
      ],
      "snippets": [
        {
          "beginSection": "title",
          "endSection": "title",
          "text": "Alternative microexon splicing by RBFOX2 and PTBP1 is associated with metastasis in colorectal cancer.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34346508",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 102
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Finally, we found that changes in the pattern of microexon splicing were associated with CRC metastasis. Our data thus suggest that altered expression of RBFOX2 and PTBP1 might influence CRC metastasis through the regulation of microexon splicing.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34346508",
          "offsetInBeginSection": 1073,
          "offsetInEndSection": 1320
        }
      ],
      "id": "63fa16d8201352f04a000002",
      "type": "factoid",
      "body": "Alternative microexon splicing is associated with metastasis in which cancer?"
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/24299589"
      ],
      "snippets": [
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "LS is a rare progressive multisystem fatal disorder inherited by autosomal recessive, X-linked and maternal transmission. ",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24299589",
          "offsetInBeginSection": 254,
          "offsetInEndSection": 376
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "LS is due to a deficit of various respiratory chain and Krebs cycle enzymes resulting in insufficient production of adenosine triphosphate (ATP), in particular cytochrome-c-oxidase (COX), pyruvate carboxylase, pyruvate dehydrogenase complex and complex I of the respiratory chain, which share an autosomal recessive and X-linked mode of transmission. Cases with maternal inheritance (MILS) are due to a mitochondrial DNA (mtDNA) point mutation.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24299589",
          "offsetInBeginSection": 587,
          "offsetInEndSection": 1031
        }
      ],
      "id": "6451034c57b1c7a315000095",
      "type": "list",
      "body": "How is Leigh syndrome inherited?"
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/34584848",
        "http://www.ncbi.nlm.nih.gov/pubmed/34527910",
        "http://www.ncbi.nlm.nih.gov/pubmed/34504629",
        "http://www.ncbi.nlm.nih.gov/pubmed/32991910",
        "http://www.ncbi.nlm.nih.gov/pubmed/33462046"
      ],
      "snippets": [
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Zinner syndrome comprises triad of seminal vesicle cyst, unilateral renal agenesis and ipsilateral ejaculatory duct obstruction. ",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34584848",
          "offsetInBeginSection": 132,
          "offsetInEndSection": 261
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "We present the case of a 51-year-old male with Zinner syndrome, which is a rare disease, resulting from an abnormal evolution of the mesonephric (Wolffian) duct. It consists in cystic dilations of one seminal vesicle and/or ejaculatory duct and ipsilateral renal agenesis.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34527910",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 272
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "A rare triad of Wolffian duct anomaly known as Zinner syndrome includes unilateral renal agenesis with ipsilateral seminal vesicle cyst and ejaculatory duct obstruction.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34504629",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 169
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Zinner syndrome, first described in 1914, refers to a triad of features consisting of seminal vesicle cysts, ejaculatory duct obstruction, and unilateral (mostly ipsilateral) renal agenesis. ",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32991910",
          "offsetInBeginSection": 149,
          "offsetInEndSection": 340
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "The triad of SV cysts, ipsilateral renal agenesis and ejaculatory duct obstruction is known as the Zinner syndrome.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33462046",
          "offsetInBeginSection": 220,
          "offsetInEndSection": 335
        }
      ],
      "id": "61f901bd882a024a10000047",
      "type": "list",
      "body": "List features of the Zinner syndrome."
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/32421805",
        "http://www.ncbi.nlm.nih.gov/pubmed/22235300",
        "http://www.ncbi.nlm.nih.gov/pubmed/26975728"
      ],
      "snippets": [
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Regulons, as groups of transcriptionally co-regulated operons, are the basic units of cellular response systems in bacterial cells.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22235300",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 131
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "A group of genes controlled as a unit, usually by the same repressor or activator gene, is known as a regulon.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32421805",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 110
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Regulons are the basic units of the response system in a bacterial cell, and each consists of a set of transcriptionally co-regulated operons.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26975728",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 142
        }
      ],
      "id": "644f0a9757b1c7a315000088",
      "type": "summary",
      "body": "What is a regulon?"
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/29298167"
      ],
      "snippets": [
        {
          "beginSection": "title",
          "endSection": "title",
          "text": "Newly Developed Skin Picking After Methylphenidate Treatment in Attention Deficit Hyperactivity Disorder: Possible Mechanisms.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29298167",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 126
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "We describe a case of skin picking developing after methylphenidate therapy for ADHD.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29298167",
          "offsetInBeginSection": 820,
          "offsetInEndSection": 905
        }
      ],
      "id": "6414c5ba690f196b51000007",
      "type": "yesno",
      "body": "Can skin picking phenotype present following methylphenidate treatment?"
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/35996994",
        "http://www.ncbi.nlm.nih.gov/pubmed/20689246",
        "http://www.ncbi.nlm.nih.gov/pubmed/32773451"
      ],
      "snippets": [
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Kennedy\u0027s disease is nearly exclusively caused by mutations in the androgen receptor encoding gene (AR).",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35996994",
          "offsetInBeginSection": 109,
          "offsetInEndSection": 213
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Spinal bulbar muscular atrophy (SBMA) is caused by a CAG repeat expansion mutation in the androgen receptor (AR) gene, and mutant AR is presumed to act in motoneurons to cause SBMA.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20689246",
          "offsetInBeginSection": 12,
          "offsetInEndSection": 193
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "spinal and bulbar muscular atrophy (SBMA), an inherited neuromuscular disorder caused by a CAG trinucleotide repeat expansion in the androgen receptor (AR) gene.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32773451",
          "offsetInBeginSection": 125,
          "offsetInEndSection": 286
        }
      ],
      "id": "6451060c57b1c7a315000096",
      "type": "factoid",
      "body": "What is the cause of spinal-bulbar muscular atrophy?"
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/34608100",
        "http://www.ncbi.nlm.nih.gov/pubmed/34606305",
        "http://www.ncbi.nlm.nih.gov/pubmed/34572294",
        "http://www.ncbi.nlm.nih.gov/pubmed/34572466",
        "http://www.ncbi.nlm.nih.gov/pubmed/33368307"
      ],
      "snippets": [
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "SUMMARY: Clinical trials demonstrated that tezepelumab, an anti-TSLP monoclonal antibody, is a promising alternative treatment for asthma that is effective also in nontype 2 asthma.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34608100",
          "offsetInBeginSection": 449,
          "offsetInEndSection": 630
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Tezepelumab in adults and adolescents with severe, uncontrolled asthma. ",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34606305",
          "offsetInBeginSection": 60,
          "offsetInEndSection": 132
        },
        {
          "beginSection": "title",
          "endSection": "title",
          "text": "In severe, uncontrolled asthma, tezepelumab reduced exacerbations and improved asthma control at 1 y.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34606305",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 101
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Tezepelumab and other anti-alarmins are thus likely to become, in the near future, valuable therapeutic options for the biological treatment of uncontrolled severe asthma.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34572294",
          "offsetInBeginSection": 970,
          "offsetInEndSection": 1141
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Omalizumab, dupilumab, and tezepelumab can directly modulate the ASM in asthma, by specifically blocking the interaction between IgE, IL-4, and TSLP, and their receptors are located on the surface of ASM cells. ",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34572466",
          "offsetInBeginSection": 1010,
          "offsetInEndSection": 1221
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "AHR has been suggested as the main treatable trait towards precision medicine in patients suffering from eosinophilic asthma, therefore, well-designed head-to-head trials are needed to compare the efficacy of those mAbs that directly target ASM contractility specifically against the AHR in severe asthma, namely omalizumab, dupilumab, and tezepelumab.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34572466",
          "offsetInBeginSection": 1409,
          "offsetInEndSection": 1761
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Tezepelumab is a human monoclonal antibody that blocks thymic stromal lymphopoietin, an epithelial cytokine involved in asthma pathogenesis. In the phase 2b PATHWAY study (ClinicalTrials.gov identifier: NCT02054130), tezepelumab significantly reduced exacerbations in adults with severe, uncontrolled asthma. ",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33368307",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 309
        },
        {
          "beginSection": "title",
          "endSection": "title",
          "text": "Pharmacokinetic and Pharmacodynamic Modeling of Tezepelumab to Guide Phase 3 Dose Selection for Patients With Severe Asthma.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33368307",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 124
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "These results support the selection of 210 mg every 4 weeks subcutaneously as the dose for phase 3 studies of tezepelumab in adults and adolescents with severe asthma.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33368307",
          "offsetInBeginSection": 1496,
          "offsetInEndSection": 1663
        }
      ],
      "id": "61f7c904882a024a10000027",
      "type": "factoid",
      "body": "Which disease can be treated using Tezepelumab?"
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/31993419"
      ],
      "snippets": [
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Enhancers are cis-regulatory elements in the genome that cooperate with promoters to control target gene transcription. Unlike promoters, enhancers are not necessarily adjacent to target genes and can exert their functions regardless of enhancer orientations, positions and spatial segregations from target genes.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31993419",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 313
        }
      ],
      "id": "644f0fd257b1c7a31500008a",
      "type": "yesno",
      "body": "Do enhancers have to be close to their gene targets?"
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/34794294",
        "http://www.ncbi.nlm.nih.gov/pubmed/8283989",
        "http://www.ncbi.nlm.nih.gov/pubmed/2801018"
      ],
      "snippets": [
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Spinal muscular atrophy (SMA) with respiratory distress type 1 (SMARD1) is an exceptionally rare type of SMA.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34794294",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 109
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "There are no convincing reports of X-linked SMA hitherto. ",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8283989",
          "offsetInBeginSection": 902,
          "offsetInEndSection": 960
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "The total AChE activity was either normal or decreased in the childhood SMA (Type 1), the other SMA groups and disease controls (ALS, X-linked SMA).",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/2801018",
          "offsetInBeginSection": 146,
          "offsetInEndSection": 294
        }
      ],
      "id": "64463f9357b1c7a31500006a",
      "type": "yesno",
      "body": "Are there any other types of Spinal Muscular Atrophy except for types 1-4?"
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/36000541",
        "http://www.ncbi.nlm.nih.gov/pubmed/36400106",
        "http://www.ncbi.nlm.nih.gov/pubmed/36459075",
        "http://www.ncbi.nlm.nih.gov/pubmed/34626563",
        "http://www.ncbi.nlm.nih.gov/pubmed/36472472"
      ],
      "snippets": [
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Zanidatamab and tislelizumab are novel monoclonal antibodies targeting HER2 and PD-1, respectively, and have shown encouraging antitumor activity in early phase studies in multiple cancers, including GEA. ",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36000541",
          "offsetInBeginSection": 164,
          "offsetInEndSection": 369
        },
        {
          "beginSection": "title",
          "endSection": "title",
          "text": "Population pharmacokinetics of zanidatamab, an anti-HER2 biparatopic antibody, in patients with advanced or metastatic cancer.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36102999",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 126
        },
        {
          "beginSection": "title",
          "endSection": "title",
          "text": "Zanidatamab, a novel bispecific antibody, for the treatment of locally advanced or metastatic HER2-expressing or HER2-amplified cancers: a phase 1, dose-escalation and expansion study.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36400106",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 184
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Zanidatamab is a humanised, bispecific monoclonal antibody directed against two non-overlapping domains of HER2. ",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36400106",
          "offsetInBeginSection": 302,
          "offsetInEndSection": 415
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Zanidatamab is safe with preliminary efficacy in multiple HER2-expressing and HER2-amplified tumors.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36459075",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 100
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Early phase trials of dabrafenib plus trametinib (BRAF and MEK inhibition) and zanidatamab (a bispecific HER2-antibody) have yielded encouraging response rates.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34626563",
          "offsetInBeginSection": 1029,
          "offsetInEndSection": 1189
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Of those in late-stage development, marketing application submissions for at least 23 may occur by the end of 2023, of which 5 are bispecific (odronextamab, erfonrilimab, linvoseltamab, zanidatamab, and talquetamab) and 2 are ADCs (datopotamab deruxtecan, and tusamitamab ravtansine).",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36472472",
          "offsetInBeginSection": 1365,
          "offsetInEndSection": 1649
        }
      ],
      "id": "63f749cf33942b094c00000a",
      "type": "summary",
      "body": "What is the mechanism of action of Zanidatamab?"
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/29315345",
        "http://www.ncbi.nlm.nih.gov/pubmed/8713055",
        "http://www.ncbi.nlm.nih.gov/pubmed/26425553"
      ],
      "snippets": [
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "The transcription factor SOX10 plays an important role in vertebrate neural crest development, including the establishment and maintenance of the melanocyte lineage. SOX10 is also highly expressed in melanoma tumors, and SOX10 expression increases with tumor progression.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29315345",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 271
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Transcription factors are proteins that bind to DNA sequences to regulate gene transcription. The transcription factor binding sites are short DNA sequences (5-20 bp long) specifically bound by one or more transcription factors.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26425553",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 228
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Transcription factors serve as integration centres of the different signal-transduction pathways affecting a given gene. It is obvious that the regulation of these regulators themselves is of crucial importance for differential gene expression during development and in terminally differentiated cells.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8713055",
          "offsetInBeginSection": 216,
          "offsetInEndSection": 518
        }
      ],
      "id": "644eae9c57b1c7a315000080",
      "type": "summary",
      "body": "Describe the function of a transcription factor such as SOX10."
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/35546709",
        "http://www.ncbi.nlm.nih.gov/pubmed/35682973"
      ],
      "snippets": [
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Friedreich\u0027s ataxia (FA) is a rare, progressive, and degenerative hereditary disorder caused by a deficiency of frataxin protein. This disease is characterised by severe neurological dysfunction and life-threatening cardiomyopathy. ",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35546709",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 232
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Friedreich\u0027s ataxia (FRDA) is a rare genetic disorder caused by mutations in the gene frataxin, encoding for a mitochondrial protein involved in iron handling and in the biogenesis of iron-sulphur clusters, and leading to progressive nervous system damage.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35682973",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 256
        }
      ],
      "id": "6450e67457b1c7a31500008e",
      "type": "summary",
      "body": "What is Friedreich\u0027s Ataxia?"
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/33609476"
      ],
      "snippets": [
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "INTERPRETATION: A similar safety profile was seen in all treatment groups. No beneficial treatment effects were recorded. Although this study did not provide evidence of efficacy in progressive supranuclear palsy, the findings provide potentially useful information for future investigations of passive immunisation using tau antibodies for progressive supranuclear palsy.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33609476",
          "offsetInBeginSection": 2991,
          "offsetInEndSection": 3363
        }
      ],
      "id": "640418af201352f04a000018",
      "type": "yesno",
      "body": "Is Tilavonemab effective for progressive supranuclear palsy?"
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/26596501",
        "http://www.ncbi.nlm.nih.gov/pubmed/7909957",
        "http://www.ncbi.nlm.nih.gov/pubmed/26596987",
        "http://www.ncbi.nlm.nih.gov/pubmed/23022097",
        "http://www.ncbi.nlm.nih.gov/pubmed/29227708"
      ],
      "snippets": [
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Homeosis is classically defined as the transformation of one body part into something that resembles another body part.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26596501",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 119
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Homeotic transformation is defined as transformation of one body part into the likeness of something else.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29227708",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 106
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "In Drosophila, the misexpression or altered activity of genes from the bithorax complex results in homeotic transformations.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7909957",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 124
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "The discovery of the broad conservation of embryonic regulatory genes across animal phyla, launched by the cloning of homeotic genes in the 1980s, was a founding event in the field of evolutionary developmental biology (evo-devo). While it had long been known that fundamental cellular processes, commonly referred to as housekeeping functions, are shared by animals and plants across the planet-processes such as the storage of information in genomic DNA, transcription, translation and the machinery for these processes, universal codon usage, and metabolic enzymes-Hox genes were different: mutations in these genes caused \"bizarre\" homeotic transformations of insect body parts that were certainly interesting but were expected to be idiosyncratic. The isolation of the genes responsible for these bizarre phenotypes turned out to be highly conserved Hox genes that play roles in embryonic patterning throughout Metazoa.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26596987",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 924
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "The study of homeotic-transformation mutants in model organisms such as Drosophila revolutionized the field of developmental biology, but how these mutants relate to human developmental defects remains to be elucidated.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23022097",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 219
        }
      ],
      "id": "644e7e4757b1c7a315000077",
      "type": "summary",
      "body": "What does the term \"homeotic transformation\" mean?"
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/35316106",
        "http://www.ncbi.nlm.nih.gov/pubmed/34032944"
      ],
      "snippets": [
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Spinal muscular atrophy (SMA) is a rare autosomal recessive neuromuscular disease which is characterised by muscle atrophy and early death in most patients. ",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35316106",
          "offsetInBeginSection": 14,
          "offsetInEndSection": 171
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": " Spinal muscular atrophy (SMA), an autosomal recessive neurodegenerative disorder of alpha motor neurons of spinal cord associated with progressive muscle weakness and hypotonia, is the most common genetic cause of infant mortality.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34032944",
          "offsetInBeginSection": 13,
          "offsetInEndSection": 245
        }
      ],
      "id": "64463cee57b1c7a315000065",
      "type": "summary",
      "body": "What is Spinal Muscular Atrophy?"
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/33986052",
        "http://www.ncbi.nlm.nih.gov/pubmed/34329347",
        "http://www.ncbi.nlm.nih.gov/pubmed/36264571",
        "http://www.ncbi.nlm.nih.gov/pubmed/33741488",
        "http://www.ncbi.nlm.nih.gov/pubmed/33713486",
        "http://www.ncbi.nlm.nih.gov/pubmed/34538426"
      ],
      "snippets": [
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": " There was low or moderate certainty evidence for a large (≥2-fold) magnitude of association between hospitalisation in people with COVID-19, and: obesity class III, heart failure, diabetes, chronic kidney disease, dementia, age \u003e45 years, male gender, black race/ethnicity (vs non-Hispanic white), homelessness and low income. Age \u003e60 and \u003e70 years may be associated with large increases in mechanical ventilation and severe disease, respectively. For mortality, a large magnitude of association may exist with liver disease, Bangladeshi ethnicity (vs British white), age \u003e45 years, age \u003e80 years (vs 65-69 years) and male gender among 20-64 years (but not older). Associations with hospitalisation and mortality may be very large (≥5-fold) for those aged ≥60 years.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33986052",
          "offsetInBeginSection": 988,
          "offsetInEndSection": 1755
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Increasing age (especially \u003e60 years) may be the most important risk factor for severe outcomes.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33986052",
          "offsetInBeginSection": 1768,
          "offsetInEndSection": 1864
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "In multivariable logistic regression analyses, increasing age (adjusted odds ratio [aOR] 1.1, 95% confidence interval [CI] 1.1-1.2, p\u003c0.001), male gender (aOR 1.8, 95% CI 1.2-2.7, p \u003d 0.002), Hispanic ethnicity (aOR 1.9, 95% CI 1.2-3.1, p \u003d 0.01), obesity (3.1, 95% CI 1.9-5.1, p\u003c0.001), asthma history (aOR 2.3, 95% CI 1.3-4.0, p \u003d 0.003), congestive heart failure (aOR 6.0, 95% CI 1.5-25.1, p \u003d 0.01), cerebrovascular disease (aOR 4.9, 95% CI 1.7-14.7, p \u003d 0.004), and diabetes (aOR 3.4, 95% CI 1.9-6.2, p\u003c0.001) were predictive of severe disease diagnoses within 30 days.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34329347",
          "offsetInBeginSection": 1108,
          "offsetInEndSection": 1682
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "The strongest association with risk of severe disease after vaccination was age, which increased among patients aged 50 years or older with an adjusted odds ratio (aOR) of 1.42 (CI, 1.40-1.44) per 5-year increase in age, such that patients aged 80 years or older had an aOR of 16.58 (CI, 13.49-20.37) relative to patients aged 45 to 50 years. Immunocompromising conditions, including receipt of different classes of immunosuppressive medications (eg, leukocyte inhibitor: aOR, 2.80; 95% CI, 2.39-3.28) or cytotoxic chemotherapy (aOR, 2.71; CI, 2.27-3.24) prior to breakthrough infection, or leukemias or lymphomas (aOR, 1.87; CI, 1.61-2.17) and chronic conditions associated with end-organ disease, such as heart failure (aOR, 1.74; CI, 1.61-1.88), dementia (aOR, 2.01; CI, 1.83-2.20), and chronic kidney disease (aOR, 1.59; CI, 1.49-1.69), were also associated with increased risk.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36264571",
          "offsetInBeginSection": 1417,
          "offsetInEndSection": 2299
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Factors associated with severe COVID-19 were older age [adjusted relative risk (aRR) 1.78, 95% confidence interval (CI) 1.61-1.97; P \u003c 0.0001], diabetes (aRR 2.00, 95% CI 1.20-3.32; P \u003d 0.007), cardiovascular disease (aRR 2.53, 95% CI 1.53-4.17; P \u003c 0.0001), malignancy (aRR 4.57, 95% CI 1.62-12.87; P \u003d 0.004), surgery/trauma (aRR 23.98, 95% CI 10.35-55.57; P \u003c 0.0001) and human immunodeficiency virus infection (aRR 4.24, 95% CI 1.55-11.61; P \u003d 005).",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33741488",
          "offsetInBeginSection": 879,
          "offsetInEndSection": 1332
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Cirrhosis was an independent predictor of severe COVID-19 in patients with AIH (P \u003c 0.001; OR, 17.46; 95% CI, 4.22-72.13).",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33713486",
          "offsetInBeginSection": 1302,
          "offsetInEndSection": 1424
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Data regarding outcome of COVID-19 in patients with autoimmune hepatitis (AIH) are lacking.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33713486",
          "offsetInBeginSection": 21,
          "offsetInEndSection": 112
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Cirrhosis was the strongest predictor for severe COVID-19 in patients with AIH.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33713486",
          "offsetInBeginSection": 1701,
          "offsetInEndSection": 1780
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": " Older age, male sex, non-White race, Hispanic ethnicity, obesity, and a higher number of chronic conditions were associated with increased risk of severe infection.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34538426",
          "offsetInBeginSection": 925,
          "offsetInEndSection": 1090
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "In particular, persons 0 to 44 years of age with cancer, chronic neurologic disorders, hematologic disorders, ischemic heart disease, and other endocrine disorders had a greater than 3-fold increased risk of severe infection compared with persons of the same age without those conditions.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34538426",
          "offsetInBeginSection": 1261,
          "offsetInEndSection": 1549
        }
      ],
      "id": "643df77457b1c7a31500003b",
      "type": "list",
      "body": "What factors are associated with severe COVID-19?"
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/35042956",
        "http://www.ncbi.nlm.nih.gov/pubmed/33394459"
      ],
      "snippets": [
        {
          "beginSection": "title",
          "endSection": "title",
          "text": "No infectious SARS-CoV-2 in breast milk from a cohort of 110 lactating women.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35042956",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 77
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "SARS-CoV-2 RNA can be found infrequently in the breastmilk after recent infection, but we found no evidence that breastmilk contains an infectious virus or that breastfeeding represents a risk factor for transmission of infection to infants.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35042956",
          "offsetInBeginSection": 1169,
          "offsetInEndSection": 1410
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "This article goes beyond prior small studies to provide evidence that infectious SARS-CoV-2 is not present in the milk of lactating women with recent infection, even when SARS-CoV-2 RNA is detected.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35042956",
          "offsetInBeginSection": 1418,
          "offsetInEndSection": 1616
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Recent SARS-CoV-2 infection or detection of its RNA in human milk is not a contraindication to breastfeeding.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35042956",
          "offsetInBeginSection": 1617,
          "offsetInEndSection": 1726
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Based on the currently available limited evidence and recognizing the benefits of breastfeeding, it may be concluded that if the health of the mother and her newborn allows, direct breastfeeding or extracted breastmilk should be encouraged by the healthcare providers after a careful discussion of the risks of vertical transmission to the mother and her family",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33394459",
          "offsetInBeginSection": 1065,
          "offsetInEndSection": 1426
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Preventive measures should be taken by COVID-19 mothers to prevent droplet transmission of infection to the infants while breastfeeding.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33394459",
          "offsetInBeginSection": 1428,
          "offsetInEndSection": 1564
        }
      ],
      "id": "641791ed690f196b51000032",
      "type": "yesno",
      "body": "Is SARS-CoV-2 transmitted through breast milk?"
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/20444609",
        "http://www.ncbi.nlm.nih.gov/pubmed/15868422"
      ],
      "snippets": [
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Our genetic information is tightly packaged into a rather ingenious nucleoprotein complex called chromatin in a manner that enables it to be rapidly accessed during genomic processes. Formation of the nucleosome, which is the fundamental unit of chromatin, occurs via a stepwise process that is reversed to enable the disassembly of nucleosomes.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20444609",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 345
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "DNA in eukaryotes is packed into chromatin. The basic component of chromatin is the nucleosome consisting of DNA wrapped around a histone octamer. Inside the cell nucleus, chromatin is folded into higher-order structures through various mechanisms, including repositioning of nucleosomes along the DNA, packing of nucleosomes into more condensed 3-dimensional configurations, looping of chromatin fibres, and tethering of chromosomal regions to nuclear structures.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15868422",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 464
        }
      ],
      "id": "644ef78f57b1c7a315000084",
      "type": "factoid",
      "body": "Chromatin is tightly packed into what structure inside the nucleus?"
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/31794465",
        "http://www.ncbi.nlm.nih.gov/pubmed/35428982"
      ],
      "snippets": [
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "The treatment of FSHD is currently supportive only.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31794465",
          "offsetInBeginSection": 1218,
          "offsetInEndSection": 1269
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Facioscapulohumeral muscular dystrophy (FSHD) is a slowly progressive muscular dystrophy without approved therapies.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35428982",
          "offsetInBeginSection": 19,
          "offsetInEndSection": 135
        }
      ],
      "id": "644284a957b1c7a31500005c",
      "type": "yesno",
      "body": "Is there any treatment for the Facioscapulohumeral Muscular Dystrophy?"
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/34016622",
        "http://www.ncbi.nlm.nih.gov/pubmed/33934105",
        "http://www.ncbi.nlm.nih.gov/pubmed/35277481",
        "http://www.ncbi.nlm.nih.gov/pubmed/27364481",
        "http://www.ncbi.nlm.nih.gov/pubmed/33299103",
        "http://www.ncbi.nlm.nih.gov/pubmed/25473436",
        "http://www.ncbi.nlm.nih.gov/pubmed/35750313"
      ],
      "snippets": [
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Recent advances in genome-wide analyses have revealed that the deregulation of distal gene regulatory elements, such as enhancers, appears in several pathophysiological conditions, including cancer. Beyond the conventional function of enhancers in recruiting transcription factors to gene promoters, enhancer elements are also transcribed into noncoding RNAs known as enhancer RNAs (eRNA). Accumulating evidence suggests that uncontrolled enhancer activity with aberrant eRNA expression promotes oncogenesis. Interestingly, tissue-specific, transcribed eRNAs from active enhancers can serve as potential therapeutic targets or biomarkers in several cancer types.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34016622",
          "offsetInBeginSection": 355,
          "offsetInEndSection": 1017
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Enhancers are cis-regulatory sequences that fine-tune expression of their target genes in a spatiotemporal manner. They are recognized by sequence-specific transcription factors, which in turn recruit transcriptional coactivators that facilitate transcription by promoting assembly and activation of the basal transcriptional machinery. Their functional importance is underscored by the fact that they are often the target of genetic and nongenetic events in human disease that disrupt their sequence, interactome, activation potential, and/or chromatin environment. Dysregulation of transcription and addiction to transcriptional effectors that interact with and modulate enhancer activity are common features of cancer cells and are amenable to therapeutic intervention.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33934105",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 772
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Enhancer is one kind of cis-elements regulating gene transcription, whose activity is tightly controlled by epigenetic enzymes and histone modifications. Active enhancers are classified into typical enhancers, super-enhancers and over-active enhancers, according to the enrichment and location of histone modifications.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35750313",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 319
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Recent studies have revealed enhancer dysregulation as one of the important features for cancer. Variations in enhancer regions and mutations of enhancer regulatory genes are frequently observed in cancer cells, and altering the activity of onco-enhancers is able to repress oncogene expression, and suppress tumorigenesis and metastasis.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35750313",
          "offsetInBeginSection": 662,
          "offsetInEndSection": 1000
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "The disruption of enhancer activity, through genetic or epigenetic alterations, can impact cell-type-specific functions, resulting in a wide range of pathologies. In cancer, these alterations can promote a \u0027cell identity crisis\u0027, in which enhancers associated with oncogenes and multipotentiality are activated, while those promoting cell fate commitment are inactivated. Overall, these alterations favor an undifferentiated cellular phenotype.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25473436",
          "offsetInBeginSection": 540,
          "offsetInEndSection": 984
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Enhancers are selectively utilized to orchestrate gene expression programs that first govern pluripotency and then proceed to highly specialized programs required for the process of cellular differentiation.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25473436",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 207
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Enhancer elements function as the logic gates of the genetic regulatory circuitry. One of their most important functions is the integration of extracellular signals with intracellular cell fate information to generate cell type-specific transcriptional responses. Mutations occurring in cancer often misregulate enhancers that normally control the signal-dependent expression of growth-related genes. This misregulation can result from trans-acting mechanisms, such as activation of the transcription factors or epigenetic regulators that control enhancer activity, or can be caused in cis by direct mutations that alter the activity of the enhancer or its target gene specificity. These processes can generate tumour type-specific super-enhancers and establish a \u0027locked\u0027 gene regulatory state that drives the uncontrolled proliferation of cancer cells.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27364481",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 854
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Transcription factors, cofactors, chromatin regulators, and transcription apparatuses interact with transcriptional regulatory elements, including promoters, enhancers, and super-enhancers (SEs), to coordinately regulate the transcription of target genes and thereby control cell behaviors. Among these transcriptional regulatory components and related elements, SEs often play a central role in determining cell identity and tumor initiation and progression. Therefore, oncogenic SEs, which are generated within cancer cells in oncogenes and other genes important in tumor pathogenesis, have emerged as attractive targets for novel cancer therapeutic strategies in recent years.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35277481",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 679
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Transcriptional dysregulation of these pathways is commonly associated with tumorigenesis and the development of cancer. Genetic and epigenetic alterations may mediate dysregulated transcriptional activity. One of the most important epigenetic alternations is the non-coding regulatory element, which includes both enhancers and super-enhancers (SEs). SEs, characterized as large clusters of enhancers with aberrant high levels of transcription factor binding, have been considered as key drivers of gene expression in controlling and maintaining cancer cell identity. In cancer cells, oncogenes acquire SEs and the cancer phenotype relies on these abnormal transcription programs driven by SEs, which leads to cancer cells often becoming addicted to the SEs-related transcription programs, including prostate cancer.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33299103",
          "offsetInBeginSection": 120,
          "offsetInEndSection": 937
        }
      ],
      "id": "644e7e5257b1c7a315000078",
      "type": "summary",
      "body": "What is the role of enhancers in cancer?"
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/36250332",
        "http://www.ncbi.nlm.nih.gov/pubmed/33664472",
        "http://www.ncbi.nlm.nih.gov/pubmed/31317627",
        "http://www.ncbi.nlm.nih.gov/pubmed/23748256"
      ],
      "snippets": [
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": " Non-pharmacological comfort measures such as breastfeeding, swaddling and sweet solutions are inconsistently implemented and are not always practical or effective in reducing the transmission of noxious input to the brain. ",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36250332",
          "offsetInBeginSection": 358,
          "offsetInEndSection": 582
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "In this comparative effectiveness research 195 neonates \u003e36 weeks\u0027 gestation were randomised to three groups, receiving during heel stick: (i) breastfeeding, (ii) sucrose 24% liquid with non-nutritive sucking and (iii) sucrose 24% gel with non-nutritive sucking. ",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33664472",
          "offsetInBeginSection": 137,
          "offsetInEndSection": 400
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "All the methods analysed has shown to be effective in reducing pain",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33664472",
          "offsetInBeginSection": 470,
          "offsetInEndSection": 537
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "There was an increase in odds of pain following liquid sucrose compared to breastfeeding (OR \u003d 1.60; 95% CI: 0.82-3.3; p \u003d 0.17).",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33664472",
          "offsetInBeginSection": 539,
          "offsetInEndSection": 668
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Sucrose 24% gel with non-nutritive sucking seems to be a valid alternative when breastfeeding is not possible. Further research is needed.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33664472",
          "offsetInBeginSection": 861,
          "offsetInEndSection": 999
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Oral sucrose is commonly given to children to reduce procedural pain.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31317627",
          "offsetInBeginSection": 195,
          "offsetInEndSection": 264
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "he present systematic review and meta-analyses demonstrate that glucose reduces pain scores and crying during single heel lances and venipunctures. Results indicate that 20% to 30% glucose solutions have analgesic effects and can be recommended as an alternative to sucrose for procedural pain reduction in healthy term and preterm neonates.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23748256",
          "offsetInBeginSection": 1508,
          "offsetInEndSection": 1849
        }
      ],
      "id": "6441371857b1c7a315000057",
      "type": "list",
      "body": "What are the currently used non-pharmacological measures for the management of procedural pain in neonates?"
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/12867081",
        "http://www.ncbi.nlm.nih.gov/pubmed/21266472",
        "http://www.ncbi.nlm.nih.gov/pubmed/15215523",
        "http://www.ncbi.nlm.nih.gov/pubmed/28369664",
        "http://www.ncbi.nlm.nih.gov/pubmed/28334756",
        "http://www.ncbi.nlm.nih.gov/pubmed/9710598"
      ],
      "snippets": [
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "The use of several translation initiation codons in a single mRNA, by expressing several proteins from a single gene, contributes to the generation of protein diversity. A small, yet growing, number of mammalian mRNAs initiate translation from a non-AUG codon, in addition to initiating at a downstream in-frame AUG codon. Translation initiation on such mRNAs results in the synthesis of proteins harbouring different amino terminal domains potentially conferring on these isoforms distinct functions.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12867081",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 501
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "In eukaryotes, it is generally assumed that translation initiation occurs at the AUG codon closest to the messenger RNA 5\u0027 cap. However, in certain cases, initiation can occur at codons differing from AUG by a single nucleotide, especially the codons CUG, UUG, GUG, ACG, AUA and AUU. While non-AUG initiation has been experimentally verified for a handful of human genes, the full extent to which this phenomenon is utilized--both for increased coding capacity and potentially also for novel regulatory mechanisms--remains unclear.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21266472",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 531
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "The removal of N-terminal translation initiator Met by methionine aminopeptidase (MetAP) is often crucial for the function and stability of proteins.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15215523",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 149
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Protein synthesis is initiated by methionine in eukaryotes and by formylmethionine in prokaryotes. N-terminal methionine can be co-translationally cleaved by the enzyme methionine aminopeptidase (MAP).",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28369664",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 201
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Our understanding of translation underpins our capacity to engineer living systems. The canonical start codon (AUG) and a few near-cognates (GUG, UUG) are considered as the \u0027start codons\u0027 for translation initiation in Escherichia coli.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28334756",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 235
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Translation from non-canonical start codons ranged from 0.007 to 3% relative to translation from AUG.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28334756",
          "offsetInBeginSection": 571,
          "offsetInEndSection": 672
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Protein synthesis is initiated universally with the amino acid methionine. In Escherichia coli, studies with anticodon sequence mutants of the initiator methionine tRNA have shown that protein synthesis can be initiated with several other amino acids. In eukaryotic systems, however, a yeast initiator tRNA aminoacylated with isoleucine was found to be inactive in initiation in mammalian cell extracts.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9710598",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 403
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Our results show that in the presence of the corresponding mutant initiator tRNAs, AGG and GUC can initiate protein synthesis in COS1 cells with methionine and valine, respectively. CAG initiates protein synthesis with glutamine but extremely poorly, whereas UAG could not be used to initiate protein synthesis with glutamine.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9710598",
          "offsetInBeginSection": 881,
          "offsetInEndSection": 1207
        }
      ],
      "id": "644e642a57b1c7a315000075",
      "type": "yesno",
      "body": "Do all proteins start with methionine?"
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/21496633"
      ],
      "snippets": [
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": " The molecular genetics of FSHD are complex, with current understanding focusing on epigenetic effects related to contraction-dependent (FSHD1) and contraction-independent (FSHD2) effects of a hypomethylated repeat sequence (D4Z4), in the presence of a specific 4qA161 phenotype. ",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21496633",
          "offsetInBeginSection": 447,
          "offsetInEndSection": 727
        }
      ],
      "id": "6442810c57b1c7a31500005a",
      "type": "list",
      "body": "Which are the types of Facioscapulohumeral Muscular Dystrophy?"
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/25803486",
        "http://www.ncbi.nlm.nih.gov/pubmed/28649789"
      ],
      "snippets": [
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Microphthalmia-associated transcription factor (MITF) is the master regulator of the melanocyte lineage.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25803486",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 104
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "MITF and SOX10 actively recruit BRG1 to a set of MITF-associated regulatory elements (MAREs) at active enhancers. Combinations of MITF, SOX10, TFAP2A, and YY1 bind between two BRG1-occupied nucleosomes thus defining both a signature of transcription factors essential for the melanocyte lineage and a specific chromatin organisation of the regulatory elements they occupy.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25803486",
          "offsetInBeginSection": 568,
          "offsetInEndSection": 940
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "MITF governs multiple steps in the development of melanocytes, including specification from neural crest, growth, survival, and terminal differentiation.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28649789",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 153
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "However, MITF does not act alone.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28649789",
          "offsetInBeginSection": 298,
          "offsetInEndSection": 331
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "ChIP-seq studies have indicated that the transcription factors SOX10, YY1, and TFAP2A co-occupy subsets of regulatory elements bound by MITF in melanocytes. Analyses at single loci also support roles for LEF1, RB1, IRF4, and PAX3 acting in combination with MITF, while sequence motif analyses suggest that additional transcription factors colocalize with MITF at many melanocyte-specific regulatory elements. However, the precise biochemical functions of each of these MITF collaborators and their contributions to gene expression remain to be elucidated.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28649789",
          "offsetInBeginSection": 427,
          "offsetInEndSection": 982
        }
      ],
      "id": "644f057357b1c7a315000087",
      "type": "list",
      "body": "Which transcription factors are essential for the melanocyte lineage?"
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/30871534"
      ],
      "snippets": [
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Facial-scapular-humeral myodystrophy Landouzy-Dejerine (FSHD) is an autosomal dominant disease, the basis of its pathogenesis is ectopic expression of the transcription factor DUX4 in skeletal muscle.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30871534",
          "offsetInBeginSection": 12,
          "offsetInEndSection": 212
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "FSHD2 is caused by the mutations in the protein regulating the methylation status of chromatin - SMCHD1.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30871534",
          "offsetInBeginSection": 480,
          "offsetInEndSection": 584
        }
      ],
      "id": "644298cc57b1c7a315000062",
      "type": "factoid",
      "body": "What is the cause of Facioscapulohumeral Muscular Dystrophy type 2 (FSHD2)?"
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/35052449",
        "http://www.ncbi.nlm.nih.gov/pubmed/32276665",
        "http://www.ncbi.nlm.nih.gov/pubmed/17852020"
      ],
      "snippets": [
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Spinal and bulbar muscular atrophy (SBMA) is an X-linked and adult-onset neurodegenerative disorder caused by the expansion of trinucleotide cytosine-adenine-guanine repeats, which encodes a polyglutamine tract in the androgen receptor gene.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35052449",
          "offsetInBeginSection": 154,
          "offsetInEndSection": 395
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Kennedy\u0027s disease (KD), also known as spinal and bulbar muscular atrophy (SBMA), is a rare, adult-onset, X-linked recessive neuromuscular disease caused by CAG expansions in exon 1 of the androgen receptor gene (AR).",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32276665",
          "offsetInBeginSection": 12,
          "offsetInEndSection": 228
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Spinal and bulbar muscular atrophy (SBMA) is an X-linked adult motor neuron disorder caused by an abnormal CAG-repeat expansion in the first exon of the androgen receptor gene. ",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17852020",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 177
        }
      ],
      "id": "6446c89e57b1c7a315000073",
      "type": "summary",
      "body": "What is Spinal-bulbar muscular atrophy (SBMA)?"
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/32022138"
      ],
      "snippets": [
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "8% of female DMD carriers have muscle weakness and cardiomyopathy. ",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32022138",
          "offsetInBeginSection": 121,
          "offsetInEndSection": 188
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Pseudohypertrophy of calf muscles, muscular weakness, compensatory movements and longer timed performance on functional tasks were observed in most of the cases. ",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32022138",
          "offsetInBeginSection": 820,
          "offsetInEndSection": 982
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Clinical manifestation of asymmetrical muscle weakness and compensatory movements, or both can be found in female carriers of DMD mutations, which can adversely affect posture and functional performance of these patients.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32022138",
          "offsetInBeginSection": 1465,
          "offsetInEndSection": 1686
        }
      ],
      "id": "6417921b690f196b51000033",
      "type": "list",
      "body": "What are common symptoms in female carriers of DMD?"
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/34540429",
        "http://www.ncbi.nlm.nih.gov/pubmed/24846915",
        "http://www.ncbi.nlm.nih.gov/pubmed/9686263",
        "http://www.ncbi.nlm.nih.gov/pubmed/32504000",
        "http://www.ncbi.nlm.nih.gov/pubmed/16775364",
        "http://www.ncbi.nlm.nih.gov/pubmed/24198383",
        "http://www.ncbi.nlm.nih.gov/pubmed/20163430"
      ],
      "snippets": [
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "There are four types: CMT1, CMT2, CMT3 and CMT4, depending upon the involvement of specific gene deficit, inheritance pattern, age of onset and whether the primary defect results in an abnormality of the myelin or axon of the nerve.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34540429",
          "offsetInBeginSection": 467,
          "offsetInEndSection": 699
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Clinically, CMT can be divided into two main types: a demyelinating type (CMT1, CMT3, CMT4 and CMTX1) and an axonal type (CMT2)",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24846915",
          "offsetInBeginSection": 141,
          "offsetInEndSection": 268
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": " CMT1, or hypertrophic form in which mutations or a duplication were found on chromosome 17 is the most frequent (CMT1A), CMT2 is the neuronal form, CMT3 is termed the Dejerine-Sottas disease, CMT4 recessive forms, CMT5 a form with associated pyramidal features, and CMTX. ",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9686263",
          "offsetInBeginSection": 467,
          "offsetInEndSection": 740
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Charcot-Marie-Tooth (CMT) is a group of inherited diseases clinically and genetically heterogenous, characterised by length dependent degeneration of axons of the peripheral nervous system. A missense mutation (p.R158H) in the pyruvate dehydrogenase kinase 3 gene (PDK3) has been identified as the genetic cause for an X-linked form of CMT (CMTX6) in two unrelated families. ",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32504000",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 375
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "The subdivision into demyelinating CMT1 and axonal CMT2 types was a milestone and is still valid for the majority of patients.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16775364",
          "offsetInBeginSection": 571,
          "offsetInEndSection": 697
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Intermediate conduction velocities are often found in males with X-linked CMT (CMTX), and different intermediate CMT types have been identified",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16775364",
          "offsetInBeginSection": 752,
          "offsetInEndSection": 895
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "The association of neuropathy and optic atrophy (also known as CMT type 6) has been described with autosomaldominant, recessive and X-linked modes of inheritance.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24198383",
          "offsetInBeginSection": 246,
          "offsetInEndSection": 408
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Mutations in Mitofusin 2 have been found to cause dominant forms of CMT6.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24198383",
          "offsetInBeginSection": 409,
          "offsetInEndSection": 482
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Mutations of the gene encoding mitofusin 2 (MFN2) have recently been identified as the cause of approximately one-third of dominantly inherited cases of the axonal degenerative forms of Charcot-Marie-Tooth disease (CMT type 2A) and of rarer variants.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20163430",
          "offsetInBeginSection": 189,
          "offsetInEndSection": 439
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "The latter include a severe, early-onset axonal neuropathy, which may occur in autosomal dominant or recessive forms, as well as some instances associated with pyramidal tract involvement (CMT type 5),",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20163430",
          "offsetInBeginSection": 440,
          "offsetInEndSection": 641
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "with optic atrophy (CMT type 6),",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20163430",
          "offsetInBeginSection": 642,
          "offsetInEndSection": 674
        }
      ],
      "id": "6446caac57b1c7a315000074",
      "type": "list",
      "body": "Which are the types of Charcot-Marie-Tooth Disease (CMT)?"
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/30871534"
      ],
      "snippets": [
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "There are two types of the disease: FSHD1 (MIM:158900) and FSHD2 (MIM: 158901), which have different genetic causes but are phenotypically indistinguishable. In FSHD1, partial deletion of the D4Z4 repeats on the 4th chromosome affects the expression of DUX4",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30871534",
          "offsetInBeginSection": 213,
          "offsetInEndSection": 470
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Facial-scapular-humeral myodystrophy Landouzy-Dejerine (FSHD) is an autosomal dominant disease, the basis of its pathogenesis is ectopic expression of the transcription factor DUX4 in skeletal muscle.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30871534",
          "offsetInBeginSection": 12,
          "offsetInEndSection": 212
        }
      ],
      "id": "6442933f57b1c7a315000060",
      "type": "factoid",
      "body": "What is the cause of Facioscapulohumeral Muscular Dystrophy type 1 (FSHD1)?"
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/35795638",
        "http://www.ncbi.nlm.nih.gov/pubmed/35721635",
        "http://www.ncbi.nlm.nih.gov/pubmed/35073857"
      ],
      "snippets": [
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Kearns Sayre Syndrome (KSS) is a rare mitochondrial disease characterized by a primary dysfunction of the mitochondrial respiratory chain. ",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35795638",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 139
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Kearns-Sayre syndrome is a rare mitochondrial disorder. It had a triad of features, including progressive external ophthalmoplegia, pigmentary retinopathy, and an alteration of cardiac conduction.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35721635",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 196
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Kearns-Sayre syndrome (KSS) is a rare, multisystem mitochondrial encephalomyopathy.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35073857",
          "offsetInBeginSection": 12,
          "offsetInEndSection": 95
        }
      ],
      "id": "6450f1b457b1c7a315000092",
      "type": "summary",
      "body": "What is Kearns-Sayre syndrome (KSS)?"
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/32026421",
        "http://www.ncbi.nlm.nih.gov/pubmed/33025945"
      ],
      "snippets": [
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Golodirsen (Vyondys 53™), an antisense oligonucleotide of the phophorodiamidate morpholino oligomer (PMO) subclass designed to induce exon 53 skipping",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32026421",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 150
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Antisense oligonucleotides, e.g., phosphorodiamidate morpholino oligomers (PMOs), can induce therapeutic exon skipping during pre-mRNA processing to restore the reading frame of the primary transcript of DMD. As a result, truncated but partially functional dystrophin is produced, potentially slowing down the disease progression.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33025945",
          "offsetInBeginSection": 452,
          "offsetInEndSection": 782
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Golodirsen is a provisionally approved PMO-based drug for approx. 8% of all DMD patients amenable to exon 53 skipping.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33025945",
          "offsetInBeginSection": 783,
          "offsetInEndSection": 901
        }
      ],
      "id": "64178f76690f196b51000026",
      "type": "summary",
      "body": "What is golodirsen\u0027s mechanism of action?"
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/36031908",
        "http://www.ncbi.nlm.nih.gov/pubmed/36250567",
        "http://www.ncbi.nlm.nih.gov/pubmed/36274837"
      ],
      "snippets": [
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": " Emery-Dreifuss Muscular Dystrophy (EDMD) is an early-onset, slowly-progressive group of myopathies, presenting with joint contractures, muscle weakness and cardiac abnormalities.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36031908",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 179
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Emery-Dreifuss muscular dystrophy (EDMD) is an uncommon, gradually progressive X-linked myopathy, and it could result in rigid spinal deformity. ",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36250567",
          "offsetInBeginSection": 12,
          "offsetInEndSection": 157
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "X-Linked Emery-Dreifuss muscular dystrophy is caused by mutations in the gene encoding emerin.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36274837",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 94
        }
      ],
      "id": "64467df857b1c7a31500006c",
      "type": "summary",
      "body": "What is Emery-Dreifuss Muscular Dystrophy (EDMD)?"
    }
  ]
}